NZ714465B2 - Dual selective pi3 delta and gamma kinase inhibitors - Google Patents
Dual selective pi3 delta and gamma kinase inhibitors Download PDFInfo
- Publication number
- NZ714465B2 NZ714465B2 NZ714465A NZ71446514A NZ714465B2 NZ 714465 B2 NZ714465 B2 NZ 714465B2 NZ 714465 A NZ714465 A NZ 714465A NZ 71446514 A NZ71446514 A NZ 71446514A NZ 714465 B2 NZ714465 B2 NZ 714465B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- compound
- cell
- disease
- compound according
- kinase
- Prior art date
Links
- 239000003757 phosphotransferase inhibitor Substances 0.000 title description 2
- 201000010099 disease Diseases 0.000 claims abstract description 63
- 108091000081 Phosphotransferases Proteins 0.000 claims abstract description 21
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 16
- 102000030951 Phosphotransferases Human genes 0.000 claims abstract 6
- 102000010400 1-phosphatidylinositol-3-kinase activity proteins Human genes 0.000 claims abstract 4
- 108040005185 1-phosphatidylinositol-3-kinase activity proteins Proteins 0.000 claims abstract 4
- 150000001875 compounds Chemical class 0.000 claims description 217
- 210000004027 cells Anatomy 0.000 claims description 137
- 230000002401 inhibitory effect Effects 0.000 claims description 72
- 239000000203 mixture Substances 0.000 claims description 48
- 239000011780 sodium chloride Substances 0.000 claims description 27
- -1 (S)(l- (9H-purinylamino)propyl)(3- fluorophenyl)-4H-chromenone Chemical compound 0.000 claims description 21
- 239000003795 chemical substances by application Substances 0.000 claims description 19
- 150000003839 salts Chemical class 0.000 claims description 17
- 239000003814 drug Substances 0.000 claims description 16
- 230000004054 inflammatory process Effects 0.000 claims description 16
- 208000006673 Asthma Diseases 0.000 claims description 15
- 206010061218 Inflammation Diseases 0.000 claims description 15
- 201000011510 cancer Diseases 0.000 claims description 13
- 206010039073 Rheumatoid arthritis Diseases 0.000 claims description 11
- 206010008958 Chronic lymphocytic leukaemia Diseases 0.000 claims description 9
- 206010024324 Leukaemias Diseases 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 9
- 206010008943 Chronic leukaemia Diseases 0.000 claims description 8
- 206010029592 Non-Hodgkin's lymphomas Diseases 0.000 claims description 8
- 230000024881 catalytic activity Effects 0.000 claims description 8
- 230000002062 proliferating Effects 0.000 claims description 8
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 7
- 230000001684 chronic Effects 0.000 claims description 7
- 208000007046 Leukemia, Myeloid, Acute Diseases 0.000 claims description 6
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 6
- 201000005510 acute lymphocytic leukemia Diseases 0.000 claims description 6
- 230000003197 catalytic Effects 0.000 claims description 6
- 200000000018 inflammatory disease Diseases 0.000 claims description 6
- 201000004681 psoriasis Diseases 0.000 claims description 6
- 210000000987 Immune System Anatomy 0.000 claims description 5
- 206010025135 Lupus erythematosus Diseases 0.000 claims description 5
- 206010025323 Lymphomas Diseases 0.000 claims description 5
- 206010025310 Other lymphomas Diseases 0.000 claims description 5
- 239000002246 antineoplastic agent Substances 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 5
- 201000002491 encephalomyelitis Diseases 0.000 claims description 5
- 206010000880 Acute myeloid leukaemia Diseases 0.000 claims description 4
- 208000003950 B-Cell Lymphoma Diseases 0.000 claims description 4
- 206010020243 Hodgkin's disease Diseases 0.000 claims description 4
- 206010038428 Renal disease Diseases 0.000 claims description 4
- 208000009899 Burkitt Lymphoma Diseases 0.000 claims description 3
- 206010039085 Rhinitis allergic Diseases 0.000 claims description 3
- 229940035295 Ting Drugs 0.000 claims description 3
- 201000010105 allergic rhinitis Diseases 0.000 claims description 3
- 230000000527 lymphocytic Effects 0.000 claims description 3
- 206010021425 Immune system disease Diseases 0.000 claims description 2
- 208000008456 Leukemia, Myelogenous, Chronic, BCR-ABL Positive Diseases 0.000 claims description 2
- 206010029151 Nephropathy Diseases 0.000 claims description 2
- 206010042971 T-cell lymphoma Diseases 0.000 claims description 2
- 201000009673 liver disease Diseases 0.000 claims description 2
- 201000008482 osteoarthritis Diseases 0.000 claims description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 229940035676 ANALGESICS Drugs 0.000 claims 1
- 229940116904 ANTIINFLAMMATORY THERAPEUTIC RADIOPHARMACEUTICALS Drugs 0.000 claims 1
- 208000003432 Bone Disease Diseases 0.000 claims 1
- 206010007541 Cardiac disease Diseases 0.000 claims 1
- 208000008466 Metabolic Disease Diseases 0.000 claims 1
- 229940074726 OPHTHALMOLOGIC ANTIINFLAMMATORY AGENTS Drugs 0.000 claims 1
- 206010038683 Respiratory disease Diseases 0.000 claims 1
- 208000007536 Thrombosis Diseases 0.000 claims 1
- 230000000202 analgesic Effects 0.000 claims 1
- 239000000730 antalgic agent Substances 0.000 claims 1
- 230000001387 anti-histamine Effects 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 239000000739 antihistaminic agent Substances 0.000 claims 1
- 201000010870 diseases of metabolism Diseases 0.000 claims 1
- 201000010238 heart disease Diseases 0.000 claims 1
- 239000003018 immunosuppressive agent Substances 0.000 claims 1
- 201000009251 multiple myeloma Diseases 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 210000000653 nervous system Anatomy 0.000 claims 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
- 201000010874 syndrome Diseases 0.000 claims 1
- 102000001253 Protein Kinases Human genes 0.000 abstract description 30
- 108060006633 Protein Kinases Proteins 0.000 abstract description 15
- 230000001404 mediated Effects 0.000 abstract description 10
- 230000000051 modifying Effects 0.000 abstract description 9
- 230000002265 prevention Effects 0.000 abstract description 3
- 150000004777 chromones Chemical class 0.000 abstract 1
- 108090000430 Phosphatidylinositol 3-Kinases Proteins 0.000 description 78
- 102000003993 Phosphatidylinositol 3-Kinases Human genes 0.000 description 77
- 238000004166 bioassay Methods 0.000 description 46
- 241001465754 Metazoa Species 0.000 description 45
- YMWUJEATGCHHMB-UHFFFAOYSA-N methylene dichloride Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 30
- 239000012530 fluid Substances 0.000 description 29
- RTZKZFJDLAIYFH-UHFFFAOYSA-N diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 28
- 239000003112 inhibitor Substances 0.000 description 28
- XEKOWRVHYACXOJ-UHFFFAOYSA-N acetic acid ethyl ester Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 27
- 230000000694 effects Effects 0.000 description 26
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 24
- 239000000543 intermediate Substances 0.000 description 24
- 210000000265 Leukocytes Anatomy 0.000 description 23
- 210000004369 Blood Anatomy 0.000 description 22
- 239000008280 blood Substances 0.000 description 22
- 210000000440 Neutrophils Anatomy 0.000 description 17
- 238000000034 method Methods 0.000 description 16
- PMZURENOXWZQFD-UHFFFAOYSA-L na2so4 Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 16
- 230000001225 therapeutic Effects 0.000 description 16
- 210000001519 tissues Anatomy 0.000 description 16
- 210000002865 immune cell Anatomy 0.000 description 15
- 239000000243 solution Substances 0.000 description 15
- 210000003979 Eosinophils Anatomy 0.000 description 14
- 150000002500 ions Chemical class 0.000 description 14
- 210000004681 Ovum Anatomy 0.000 description 13
- 235000019504 cigarettes Nutrition 0.000 description 13
- 210000002540 Macrophages Anatomy 0.000 description 12
- 239000011541 reaction mixture Substances 0.000 description 12
- 230000004044 response Effects 0.000 description 12
- 239000007787 solid Substances 0.000 description 12
- 238000003419 tautomerization reaction Methods 0.000 description 12
- 102100019935 PPAN Human genes 0.000 description 11
- 108060006542 PPAN Proteins 0.000 description 11
- 230000037396 body weight Effects 0.000 description 11
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 11
- 239000002158 endotoxin Substances 0.000 description 11
- 108091007934 protein kinase B family Proteins 0.000 description 11
- 230000011664 signaling Effects 0.000 description 11
- 239000000779 smoke Substances 0.000 description 11
- 239000003981 vehicle Substances 0.000 description 11
- 206010003246 Arthritis Diseases 0.000 description 10
- 230000000865 phosphorylative Effects 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 210000004072 Lung Anatomy 0.000 description 9
- 239000008188 pellet Substances 0.000 description 9
- 238000006366 phosphorylation reaction Methods 0.000 description 9
- 210000003719 B-Lymphocytes Anatomy 0.000 description 8
- 206010028980 Neoplasm Diseases 0.000 description 8
- 108010029485 Protein Isoforms Proteins 0.000 description 8
- 102000001708 Protein Isoforms Human genes 0.000 description 8
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N Triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 8
- 229910002092 carbon dioxide Inorganic materials 0.000 description 8
- 230000001413 cellular Effects 0.000 description 8
- 238000004440 column chromatography Methods 0.000 description 8
- 238000001764 infiltration Methods 0.000 description 8
- 239000002609 media Substances 0.000 description 8
- 230000035755 proliferation Effects 0.000 description 8
- 229910052938 sodium sulfate Inorganic materials 0.000 description 8
- 235000011152 sodium sulphate Nutrition 0.000 description 8
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
- 108090000695 Cytokines Proteins 0.000 description 7
- 102000004127 Cytokines Human genes 0.000 description 7
- 241000229754 Iva xanthiifolia Species 0.000 description 7
- 241000700159 Rattus Species 0.000 description 7
- 239000006285 cell suspension Substances 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 230000028709 inflammatory response Effects 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 210000000601 Blood Cells Anatomy 0.000 description 6
- 241000700198 Cavia Species 0.000 description 6
- 206010015150 Erythema Diseases 0.000 description 6
- 210000001503 Joints Anatomy 0.000 description 6
- 241000700157 Rattus norvegicus Species 0.000 description 6
- 239000012043 crude product Substances 0.000 description 6
- 230000002354 daily Effects 0.000 description 6
- 230000004069 differentiation Effects 0.000 description 6
- 231100000673 dose–response relationship Toxicity 0.000 description 6
- 229940079593 drugs Drugs 0.000 description 6
- BDAGIHXWWSANSR-UHFFFAOYSA-N formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 6
- 238000004128 high performance liquid chromatography Methods 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 230000001939 inductive effect Effects 0.000 description 6
- 230000014759 maintenance of location Effects 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 230000000877 morphologic Effects 0.000 description 6
- 230000037361 pathway Effects 0.000 description 6
- 239000003208 petroleum Substances 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
- 102000007469 Actins Human genes 0.000 description 5
- 108010085238 Actins Proteins 0.000 description 5
- 206010002091 Anaesthesia Diseases 0.000 description 5
- 206010059512 Apoptosis Diseases 0.000 description 5
- 210000000138 Mast Cells Anatomy 0.000 description 5
- 229960002329 Methacholine Drugs 0.000 description 5
- 210000001744 T-Lymphocytes Anatomy 0.000 description 5
- 210000003437 Trachea Anatomy 0.000 description 5
- 206010052779 Transplant rejections Diseases 0.000 description 5
- 230000037005 anaesthesia Effects 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 230000006907 apoptotic process Effects 0.000 description 5
- 230000001363 autoimmune Effects 0.000 description 5
- 231100000321 erythema Toxicity 0.000 description 5
- 230000001965 increased Effects 0.000 description 5
- 230000002757 inflammatory Effects 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- NZWOPGCLSHLLPA-UHFFFAOYSA-N methacholine Chemical compound C[N+](C)(C)CC(C)OC(C)=O NZWOPGCLSHLLPA-UHFFFAOYSA-N 0.000 description 5
- 238000003305 oral gavage Methods 0.000 description 5
- 210000000056 organs Anatomy 0.000 description 5
- 230000000144 pharmacologic effect Effects 0.000 description 5
- 239000000651 prodrug Substances 0.000 description 5
- 229940002612 prodrugs Drugs 0.000 description 5
- 230000002829 reduced Effects 0.000 description 5
- 239000012192 staining solution Substances 0.000 description 5
- 210000000130 stem cell Anatomy 0.000 description 5
- 230000002522 swelling Effects 0.000 description 5
- 238000002054 transplantation Methods 0.000 description 5
- 238000001262 western blot Methods 0.000 description 5
- 206010003816 Autoimmune disease Diseases 0.000 description 4
- 210000001185 Bone Marrow Anatomy 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 206010021972 Inflammatory bowel disease Diseases 0.000 description 4
- 210000003127 Knee Anatomy 0.000 description 4
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 4
- PRQROPMIIGLWRP-UHFFFAOYSA-N N-formyl-methionyl-leucyl-phenylalanin Chemical compound CSCCC(NC=O)C(=O)NC(CC(C)C)C(=O)NC(C(O)=O)CC1=CC=CC=C1 PRQROPMIIGLWRP-UHFFFAOYSA-N 0.000 description 4
- 229940092253 Ovalbumin Drugs 0.000 description 4
- 108010058846 Ovalbumin Proteins 0.000 description 4
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 4
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 4
- 208000002200 Respiratory Hypersensitivity Diseases 0.000 description 4
- 206010070834 Sensitisation Diseases 0.000 description 4
- 210000002966 Serum Anatomy 0.000 description 4
- 210000003491 Skin Anatomy 0.000 description 4
- ZSZXYWFCIKKZBT-ZVDPZPSOSA-N [(2R)-3-[[(2S,3S,5R,6S)-2,6-dihydroxy-3,4,5-triphosphonooxycyclohexyl]oxy-hydroxyphosphoryl]oxy-2-hexadecanoyloxypropyl] hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCC)COP(O)(=O)OC1[C@H](O)[C@H](OP(O)(O)=O)C(OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H]1O ZSZXYWFCIKKZBT-ZVDPZPSOSA-N 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 230000001154 acute Effects 0.000 description 4
- 229940037003 alum Drugs 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 230000001093 anti-cancer Effects 0.000 description 4
- 108090001123 antibodies Proteins 0.000 description 4
- 102000004965 antibodies Human genes 0.000 description 4
- 201000008937 atopic dermatitis Diseases 0.000 description 4
- 230000000747 cardiac effect Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 210000002950 fibroblast Anatomy 0.000 description 4
- 238000000684 flow cytometry Methods 0.000 description 4
- 210000004744 fore-foot Anatomy 0.000 description 4
- 230000014725 late viral mRNA transcription Effects 0.000 description 4
- 229940021182 non-steroidal anti-inflammatory drugs Drugs 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 230000008313 sensitization Effects 0.000 description 4
- 230000001235 sensitizing Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 210000003423 Ankle Anatomy 0.000 description 3
- 102100019461 CD28 Human genes 0.000 description 3
- 101700033362 CD28 Proteins 0.000 description 3
- 102100005827 CD63 Human genes 0.000 description 3
- 101700052224 CD63 Proteins 0.000 description 3
- 102000003952 Caspase 3 Human genes 0.000 description 3
- 108090000397 Caspase 3 Proteins 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- 102100010813 EGF Human genes 0.000 description 3
- 101700033006 EGF Proteins 0.000 description 3
- 210000002889 Endothelial Cells Anatomy 0.000 description 3
- 229940088598 Enzyme Drugs 0.000 description 3
- 210000002683 Foot Anatomy 0.000 description 3
- 206010018364 Glomerulonephritis Diseases 0.000 description 3
- 201000006743 Hodgkin's lymphoma Diseases 0.000 description 3
- 210000004969 Inflammatory Cells Anatomy 0.000 description 3
- 206010022114 Injury Diseases 0.000 description 3
- 208000000429 Leukemia, Lymphocytic, Chronic, B-Cell Diseases 0.000 description 3
- 210000002381 Plasma Anatomy 0.000 description 3
- 101710040537 TNF Proteins 0.000 description 3
- 108060008444 TPR Proteins 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 3
- 230000000172 allergic Effects 0.000 description 3
- 230000000735 allogeneic Effects 0.000 description 3
- 108010092132 anti-IgM Proteins 0.000 description 3
- 230000003110 anti-inflammatory Effects 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 230000000903 blocking Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 230000020411 cell activation Effects 0.000 description 3
- 239000008004 cell lysis buffer Substances 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 229960005188 collagen Drugs 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 201000003883 cystic fibrosis Diseases 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 230000003247 decreasing Effects 0.000 description 3
- 230000001419 dependent Effects 0.000 description 3
- 230000003292 diminished Effects 0.000 description 3
- 210000000548 hind-foot Anatomy 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 230000000977 initiatory Effects 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 238000011068 load Methods 0.000 description 3
- 230000005012 migration Effects 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000006011 modification reaction Methods 0.000 description 3
- 201000006417 multiple sclerosis Diseases 0.000 description 3
- 239000000546 pharmaceutic aid Substances 0.000 description 3
- 230000002685 pulmonary Effects 0.000 description 3
- 201000009732 pulmonary eosinophilia Diseases 0.000 description 3
- 108091007921 receptor tyrosine kinases Proteins 0.000 description 3
- 102000027656 receptor tyrosine kinases Human genes 0.000 description 3
- 230000002441 reversible Effects 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 125000001424 substituent group Chemical group 0.000 description 3
- YZCKVEUIGOORGS-NJFSPNSNSA-N tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 3
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2R,3R,4S,5R,6S)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2S,3R,4S,5R,6R)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2R,3R,4S,5R,6R)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- GCNTZFIIOFTKIY-UHFFFAOYSA-N 1H-pyridin-4-one Chemical compound OC1=CC=NC=C1 GCNTZFIIOFTKIY-UHFFFAOYSA-N 0.000 description 2
- PUYVJBBSBPUKBT-AWEZNQCLSA-N 2-[(1S)-1-[(2-amino-7H-purin-6-yl)amino]ethyl]-5-methyl-3-(2-methylphenyl)quinazolin-4-one Chemical compound C1([C@@H](NC=2C=3NC=NC=3N=C(N)N=2)C)=NC2=CC=CC(C)=C2C(=O)N1C1=CC=CC=C1C PUYVJBBSBPUKBT-AWEZNQCLSA-N 0.000 description 2
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 2
- 206010000565 Acquired immunodeficiency syndrome Diseases 0.000 description 2
- VSCWAEJMTAWNJL-UHFFFAOYSA-K Aluminium chloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 2
- 208000007502 Anemia Diseases 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- 208000005783 Autoimmune Thyroiditis Diseases 0.000 description 2
- 210000003651 Basophils Anatomy 0.000 description 2
- 210000004556 Brain Anatomy 0.000 description 2
- 210000004087 Cornea Anatomy 0.000 description 2
- 210000004443 Dendritic Cells Anatomy 0.000 description 2
- 229960003957 Dexamethasone Drugs 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N Dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- 206010012601 Diabetes mellitus Diseases 0.000 description 2
- 108090000045 G-protein coupled receptors Proteins 0.000 description 2
- 102000003688 G-protein coupled receptors Human genes 0.000 description 2
- 206010018651 Graft versus host disease Diseases 0.000 description 2
- 208000009329 Graft vs Host Disease Diseases 0.000 description 2
- JNWBBCNCSMBKNE-UHFFFAOYSA-N HATU Chemical compound F[P-](F)(F)(F)(F)F.C1=CN=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 JNWBBCNCSMBKNE-UHFFFAOYSA-N 0.000 description 2
- 230000036499 Half live Effects 0.000 description 2
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 2
- 108010044467 Isoenzymes Proteins 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 206010027476 Metastasis Diseases 0.000 description 2
- 208000010125 Myocardial Infarction Diseases 0.000 description 2
- 206010053643 Neurodegenerative disease Diseases 0.000 description 2
- 206010029379 Neutrophilia Diseases 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N Oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 108050006987 Poxvirus Proteins 0.000 description 2
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 2
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 2
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 description 2
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 description 2
- 208000005069 Pulmonary Fibrosis Diseases 0.000 description 2
- 101710009384 SRC Proteins 0.000 description 2
- 241000710960 Sindbis virus Species 0.000 description 2
- 210000001685 Thyroid Gland Anatomy 0.000 description 2
- 210000002700 Urine Anatomy 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000000240 adjuvant Effects 0.000 description 2
- 230000002009 allergen Effects 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007172 antigens Proteins 0.000 description 2
- 102000038129 antigens Human genes 0.000 description 2
- 230000002917 arthritic Effects 0.000 description 2
- 201000001320 atherosclerosis Diseases 0.000 description 2
- 125000004429 atoms Chemical group 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 230000012292 cell migration Effects 0.000 description 2
- 230000033077 cellular process Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000002113 chemopreventative Effects 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000003246 corticosteroid Substances 0.000 description 2
- 230000001186 cumulative Effects 0.000 description 2
- 239000000824 cytostatic agent Substances 0.000 description 2
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 2
- 201000004624 dermatitis Diseases 0.000 description 2
- 231100000406 dermatitis Toxicity 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 230000001586 eradicative Effects 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 238000005755 formation reaction Methods 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 230000002068 genetic Effects 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 201000005787 hematologic cancer Diseases 0.000 description 2
- 238000002868 homogeneous time resolved fluorescence Methods 0.000 description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
- 230000004047 hyperresponsiveness Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 239000000411 inducer Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000003834 intracellular Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000003211 malignant Effects 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 231100000682 maximum tolerated dose Toxicity 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 201000003793 myelodysplastic syndrome Diseases 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N n-butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 238000002663 nebulization Methods 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 239000000123 paper Substances 0.000 description 2
- 238000007747 plating Methods 0.000 description 2
- VVWRJUBEIPHGQF-MDZDMXLPSA-N propan-2-yl (NE)-N-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)\N=N\C(=O)OC(C)C VVWRJUBEIPHGQF-MDZDMXLPSA-N 0.000 description 2
- 230000002285 radioactive Effects 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 230000003393 splenic Effects 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 200000000020 tissue injury Diseases 0.000 description 2
- ZMANZCXQSJIPKH-UHFFFAOYSA-N triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 2
- 229910052722 tritium Inorganic materials 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 239000011534 wash buffer Substances 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- HNLVMIYYKOKWEH-SNVBAGLBSA-N (2R)-2-phenylmethoxybutanoic acid Chemical compound CC[C@H](C(O)=O)OCC1=CC=CC=C1 HNLVMIYYKOKWEH-SNVBAGLBSA-N 0.000 description 1
- MLZLLFGVXUKQFM-UHFFFAOYSA-N 2-(3-fluorophenyl)-1-(2-hydroxyphenyl)ethanone Chemical compound OC1=CC=CC=C1C(=O)CC1=CC=CC(F)=C1 MLZLLFGVXUKQFM-UHFFFAOYSA-N 0.000 description 1
- MWGATWIBSKHFMR-UHFFFAOYSA-N 2-anilinoethanol Chemical compound OCCNC1=CC=CC=C1 MWGATWIBSKHFMR-UHFFFAOYSA-N 0.000 description 1
- KPGXRSRHYNQIFN-UHFFFAOYSA-L 2-oxoglutarate(2-) Chemical class [O-]C(=O)CCC(=O)C([O-])=O KPGXRSRHYNQIFN-UHFFFAOYSA-L 0.000 description 1
- SKDLNYCHJKDQEJ-CQSZACIVSA-N 3-(3-fluorophenyl)-2-[(1R)-1-hydroxypropyl]chromen-4-one Chemical compound CC[C@@H](O)C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC(F)=C1 SKDLNYCHJKDQEJ-CQSZACIVSA-N 0.000 description 1
- HDXDQPRPFRKGKZ-INIZCTEOSA-N 3-(3-fluorophenyl)-2-[(1S)-1-(7H-purin-6-ylamino)propyl]chromen-4-one Chemical compound C=1([C@@H](NC=2C=3NC=NC=3N=CN=2)CC)OC2=CC=CC=C2C(=O)C=1C1=CC=CC(F)=C1 HDXDQPRPFRKGKZ-INIZCTEOSA-N 0.000 description 1
- GICMHQJTKXNMGB-UHFFFAOYSA-N 4-(5-methoxy-1-benzofuran-2-yl)aniline Chemical compound C=1C2=CC(OC)=CC=C2OC=1C1=CC=C(N)C=C1 GICMHQJTKXNMGB-UHFFFAOYSA-N 0.000 description 1
- POILWHVDKZOXJZ-UHFFFAOYSA-N 4-hydroxypent-3-en-2-one Chemical compound CC(O)=CC(C)=O POILWHVDKZOXJZ-UHFFFAOYSA-N 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N 5-flurouricil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- AOJJSUZBOXZQNB-TZSSRYMLSA-N ADRIAMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 1
- 206010065040 AIDS dementia complex Diseases 0.000 description 1
- 229940100197 ANTIMETABOLITES Drugs 0.000 description 1
- YRKCREAYFQTBPV-UHFFFAOYSA-N Acetylacetone Chemical compound CC(=O)CC(C)=O YRKCREAYFQTBPV-UHFFFAOYSA-N 0.000 description 1
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 1
- 229910002016 Aerosil® 200 Inorganic materials 0.000 description 1
- 206010001897 Alzheimer's disease Diseases 0.000 description 1
- 206010002026 Amyotrophic lateral sclerosis Diseases 0.000 description 1
- 208000009094 Anemia, Hemolytic, Autoimmune Diseases 0.000 description 1
- 210000001737 Ankle Joint Anatomy 0.000 description 1
- 102000004121 Annexin A5 Human genes 0.000 description 1
- 108090000672 Annexin A5 Proteins 0.000 description 1
- 206010002967 Aplastic anaemia Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 206010003119 Arrhythmia Diseases 0.000 description 1
- 102000003852 Autoantibodies Human genes 0.000 description 1
- 108090000206 Autoantibodies Proteins 0.000 description 1
- 229920003084 Avicel® PH-102 Polymers 0.000 description 1
- 101710042656 BQ2027_MB1231C Proteins 0.000 description 1
- WGQKYBSKWIADBV-UHFFFAOYSA-N Benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 1
- 210000000941 Bile Anatomy 0.000 description 1
- 208000006386 Bone Resorption Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 210000000481 Breast Anatomy 0.000 description 1
- 206010066091 Bronchial hyperreactivity Diseases 0.000 description 1
- 206010006482 Bronchospasm Diseases 0.000 description 1
- 101700070842 CCR3 Proteins 0.000 description 1
- 102100005861 CCR3 Human genes 0.000 description 1
- HDXDQPRPFRKGKZ-MRXNPFEDSA-N CC[C@@H](Nc1ncnc2[nH]cnc12)c1oc2ccccc2c(=O)c1-c1cccc(F)c1 Chemical compound CC[C@@H](Nc1ncnc2[nH]cnc12)c1oc2ccccc2c(=O)c1-c1cccc(F)c1 HDXDQPRPFRKGKZ-MRXNPFEDSA-N 0.000 description 1
- 210000001266 CD8-Positive T-Lymphocytes Anatomy 0.000 description 1
- 101700067048 CDC13 Proteins 0.000 description 1
- 102100002226 CXCR3 Human genes 0.000 description 1
- 101700079756 CXCR3 Proteins 0.000 description 1
- 240000002804 Calluna vulgaris Species 0.000 description 1
- 235000007575 Calluna vulgaris Nutrition 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Calypsol Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- 206010058019 Cancer pain Diseases 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 206010007521 Cardiac arrhythmias Diseases 0.000 description 1
- 210000000845 Cartilage Anatomy 0.000 description 1
- 240000007857 Castanea sativa Species 0.000 description 1
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 1
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
- 210000003169 Central Nervous System Anatomy 0.000 description 1
- 210000001175 Cerebrospinal Fluid Anatomy 0.000 description 1
- 210000003679 Cervix Uteri Anatomy 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 229960001231 Choline Drugs 0.000 description 1
- 102000004353 Class I Phosphatidylinositol 3-Kinases Human genes 0.000 description 1
- 108010017000 Class I Phosphatidylinositol 3-Kinases Proteins 0.000 description 1
- 102000032176 Class I family Human genes 0.000 description 1
- 108091009220 Class I family Proteins 0.000 description 1
- 102000000503 Collagen Type II Human genes 0.000 description 1
- 108010041390 Collagen Type II Proteins 0.000 description 1
- 210000001072 Colon Anatomy 0.000 description 1
- 229940064701 Corticosteroid nasal preparations for topical use Drugs 0.000 description 1
- 229960001334 Corticosteroids Drugs 0.000 description 1
- 229960003067 Cystine Drugs 0.000 description 1
- MTCFGRXMJLQNBG-UWTATZPHSA-N D-serine Chemical compound OC[C@@H](N)C(O)=O MTCFGRXMJLQNBG-UWTATZPHSA-N 0.000 description 1
- 102000003915 DNA Topoisomerases Human genes 0.000 description 1
- 108090000323 DNA Topoisomerases Proteins 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 206010051392 Diapedesis Diseases 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- 206010012818 Diffuse large B-cell lymphoma Diseases 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N Docetaxel Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- 229960004679 Doxorubicin Drugs 0.000 description 1
- 102000001556 EC 2.7.1.67 Human genes 0.000 description 1
- 108010029190 EC 2.7.1.67 Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 229940110715 ENZYMES FOR TREATMENT OF WOUNDS AND ULCERS Drugs 0.000 description 1
- 102100009831 EPHB4 Human genes 0.000 description 1
- 101700032546 EPHB4 Proteins 0.000 description 1
- 210000000624 Ear Auricle Anatomy 0.000 description 1
- 229940116977 Epidermal Growth Factor Drugs 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 229940082789 Erbitux Drugs 0.000 description 1
- 229960001433 Erlotinib Drugs 0.000 description 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N Erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 1
- 210000003238 Esophagus Anatomy 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N Etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 Etoposide Drugs 0.000 description 1
- 102100015593 FER Human genes 0.000 description 1
- 101700086859 FER Proteins 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 229960002949 Fluorouracil Drugs 0.000 description 1
- 102000013446 GTP Phosphohydrolases Human genes 0.000 description 1
- 108091006093 GTPases Proteins 0.000 description 1
- 210000000232 Gallbladder Anatomy 0.000 description 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N Gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 229940097043 Glucuronic Acid Drugs 0.000 description 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N Glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 1
- 229960003180 Glutathione Drugs 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 210000000224 Granular leucocyte Anatomy 0.000 description 1
- 102000009465 Growth Factor Receptors Human genes 0.000 description 1
- 108010009202 Growth Factor Receptors Proteins 0.000 description 1
- 102100007203 HCK Human genes 0.000 description 1
- 101700028224 HCK Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 208000005209 Hematologic Disease Diseases 0.000 description 1
- 208000006454 Hepatitis Diseases 0.000 description 1
- 229940022353 Herceptin Drugs 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 241000701806 Human papillomavirus Species 0.000 description 1
- 229960002591 Hydroxyproline Drugs 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 229960000310 ISOLEUCINE Drugs 0.000 description 1
- 206010027665 Immune disorder Diseases 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N Inositol Chemical group O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N Intaxel Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 102000003812 Interleukin-15 Human genes 0.000 description 1
- 108090000172 Interleukin-15 Proteins 0.000 description 1
- 229940044173 Iodine-125 Drugs 0.000 description 1
- 229940084651 Iressa Drugs 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- FABUFPQFXZVHFB-CFWQTKTJSA-N Ixabepilone Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@H](C)C(=O)C(C)(C)[C@H](O)CC(=O)N1)O)C)=C\C1=CSC(C)=N1 FABUFPQFXZVHFB-CFWQTKTJSA-N 0.000 description 1
- 206010023232 Joint swelling Diseases 0.000 description 1
- 102100013180 KDR Human genes 0.000 description 1
- 208000007766 Kaposi Sarcoma Diseases 0.000 description 1
- 210000003734 Kidney Anatomy 0.000 description 1
- 208000001083 Kidney Disease Diseases 0.000 description 1
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-2-aminohexanoic acid zwitterion Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 150000000994 L-ascorbates Chemical class 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine zwitterion Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
- CZQHHVNHHHRRDU-UHFFFAOYSA-N LY294002 Chemical compound C1=CC=C2C(=O)C=C(N3CCOCC3)OC2=C1C1=CC=CC=C1 CZQHHVNHHHRRDU-UHFFFAOYSA-N 0.000 description 1
- 210000001821 Langerhans Cells Anatomy 0.000 description 1
- 241001523179 Lasia <small-headed fly> Species 0.000 description 1
- 206010024378 Leukocytosis Diseases 0.000 description 1
- 206010024379 Leukocytosis Diseases 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 210000004185 Liver Anatomy 0.000 description 1
- 208000009856 Lung Disease Diseases 0.000 description 1
- 210000004698 Lymphocytes Anatomy 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 238000000719 MTS assay Methods 0.000 description 1
- 231100000070 MTS assay Toxicity 0.000 description 1
- 210000001132 Macrophages, Alveolar Anatomy 0.000 description 1
- 206010025650 Malignant melanoma Diseases 0.000 description 1
- 206010026798 Mantle cell lymphomas Diseases 0.000 description 1
- 229960003105 Metformin Drugs 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N Methyl iodide Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 210000001616 Monocytes Anatomy 0.000 description 1
- 206010028417 Myasthenia gravis Diseases 0.000 description 1
- 206010028549 Myeloid leukaemia Diseases 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N N'-amino-N-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- WNYIBZHOMJZDKN-UHFFFAOYSA-N N-(2-acetamidoethyl)acetamide Chemical compound CC(=O)NCCNC(C)=O WNYIBZHOMJZDKN-UHFFFAOYSA-N 0.000 description 1
- 102100018369 NF1 Human genes 0.000 description 1
- 101700072759 NF1 Proteins 0.000 description 1
- 208000007538 Neurilemmoma Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 208000009905 Neurofibromatosis Diseases 0.000 description 1
- 210000001331 Nose Anatomy 0.000 description 1
- 210000001672 Ovary Anatomy 0.000 description 1
- 102100004940 PDGFRA Human genes 0.000 description 1
- 101710018349 PDGFRA Proteins 0.000 description 1
- 101710027440 PIK3CA Proteins 0.000 description 1
- 102100019471 PIK3CA Human genes 0.000 description 1
- 101710027441 PIK3CB Proteins 0.000 description 1
- 102100019474 PIK3CB Human genes 0.000 description 1
- 229960001592 Paclitaxel Drugs 0.000 description 1
- 210000000496 Pancreas Anatomy 0.000 description 1
- 102000016387 Pancreatic Elastase Human genes 0.000 description 1
- 108010067372 Pancreatic Elastase Proteins 0.000 description 1
- 241001111421 Pannus Species 0.000 description 1
- 206010061536 Parkinson's disease Diseases 0.000 description 1
- 102000035443 Peptidases Human genes 0.000 description 1
- 108091005771 Peptidases Proteins 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-M Perchlorate Chemical class [O-]Cl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-M 0.000 description 1
- 210000001428 Peripheral Nervous System Anatomy 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 210000002307 Prostate Anatomy 0.000 description 1
- 229940024999 Proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 208000007014 Retinitis Pigmentosa Diseases 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 102000001332 SRC Human genes 0.000 description 1
- 210000003296 Saliva Anatomy 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 241000580858 Simian-Human immunodeficiency virus Species 0.000 description 1
- 206010040767 Sjogren's syndrome Diseases 0.000 description 1
- 206010040844 Skin exfoliation Diseases 0.000 description 1
- 208000002320 Spinal Muscular Atrophy Diseases 0.000 description 1
- 206010041823 Squamous cell carcinoma Diseases 0.000 description 1
- 210000002784 Stomach Anatomy 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 229940006509 Strontium-89 Drugs 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 102100016327 TEK Human genes 0.000 description 1
- 101710037124 TEK Proteins 0.000 description 1
- 102100008416 TSPYL2 Human genes 0.000 description 1
- 101710036648 TSPYL2 Proteins 0.000 description 1
- 210000000538 Tail Anatomy 0.000 description 1
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 1
- 229960001603 Tamoxifen Drugs 0.000 description 1
- 208000001608 Teratocarcinoma Diseases 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- 229910052776 Thorium Inorganic materials 0.000 description 1
- 206010043554 Thrombocytopenia Diseases 0.000 description 1
- 206010043778 Thyroiditis Diseases 0.000 description 1
- 230000036335 Tissue distribution Effects 0.000 description 1
- 239000000317 Topoisomerase II Inhibitor Substances 0.000 description 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N Topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
- 231100000765 Toxin Toxicity 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 230000036462 Unbound Effects 0.000 description 1
- 210000003932 Urinary Bladder Anatomy 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- 206010046914 Vaginal infection Diseases 0.000 description 1
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 210000003462 Veins Anatomy 0.000 description 1
- 206010047461 Viral infection Diseases 0.000 description 1
- 208000001756 Virus Disease Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- QDLHCMPXEPAAMD-QAIWCSMKSA-N Wortmannin Chemical compound C1([C@]2(C)C3=C(C4=O)OC=C3C(=O)O[C@@H]2COC)=C4[C@@H]2CCC(=O)[C@@]2(C)C[C@H]1OC(C)=O QDLHCMPXEPAAMD-QAIWCSMKSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- QQINRWTZWGJFDB-UHFFFAOYSA-N actinium Chemical compound [Ac] QQINRWTZWGJFDB-UHFFFAOYSA-N 0.000 description 1
- 229910052767 actinium Inorganic materials 0.000 description 1
- 230000002730 additional Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 201000005794 allergic hypersensitivity disease Diseases 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminum Chemical class [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 238000001949 anaesthesia Methods 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 229940121369 angiogenesis inhibitors Drugs 0.000 description 1
- 230000003042 antagnostic Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 229960000070 antineoplastic Monoclonal antibodies Drugs 0.000 description 1
- 229940045988 antineoplastic drugs Protein kinase inhibitors Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 230000002238 attenuated Effects 0.000 description 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 1
- 201000009596 autoimmune hypersensitivity disease Diseases 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical class [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- 238000010256 biochemical assay Methods 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 230000024279 bone resorption Effects 0.000 description 1
- 150000001642 boronic acid derivatives Chemical class 0.000 description 1
- 230000036427 bronchial hyperreactivity Effects 0.000 description 1
- 230000003435 bronchoconstrictive Effects 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 201000009030 carcinoma Diseases 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 229920002083 cellular DNA Polymers 0.000 description 1
- 229920002092 cellular RNA Polymers 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000002490 cerebral Effects 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- 239000012069 chiral reagent Substances 0.000 description 1
- CRBHXDCYXIISFC-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CC[O-] CRBHXDCYXIISFC-UHFFFAOYSA-N 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 238000010192 crystallographic characterization Methods 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000001086 cytosolic Effects 0.000 description 1
- 230000001085 cytostatic Effects 0.000 description 1
- 230000001472 cytotoxic Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000004059 degradation Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 201000001981 dermatomyositis Diseases 0.000 description 1
- 230000035618 desquamation Effects 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 201000009910 diseases by infectious agent Diseases 0.000 description 1
- 239000002612 dispersion media Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 230000000534 elicitor Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing Effects 0.000 description 1
- 230000002255 enzymatic Effects 0.000 description 1
- 229930013356 epothilones Natural products 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N ethanolamine Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 201000008808 fibrosarcoma Diseases 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N fumaric acid Chemical class OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 230000002538 fungal Effects 0.000 description 1
- 229960002584 gefitinib Drugs 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000010363 gene targeting Methods 0.000 description 1
- 150000002315 glycerophosphates Chemical class 0.000 description 1
- 150000002357 guanidines Chemical class 0.000 description 1
- 230000003394 haemopoietic Effects 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxyl anion Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 230000001969 hypertrophic Effects 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 230000000495 immunoinflammatory Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 229940121354 immunomodulators Drugs 0.000 description 1
- 230000001861 immunosuppresant Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000000266 injurious Effects 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 230000003434 inspiratory Effects 0.000 description 1
- 230000002452 interceptive Effects 0.000 description 1
- 238000009114 investigational therapy Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000000302 ischemic Effects 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 230000000155 isotopic Effects 0.000 description 1
- 229960002014 ixabepilone Drugs 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 238000000021 kinase assay Methods 0.000 description 1
- 230000003902 lesions Effects 0.000 description 1
- 230000000670 limiting Effects 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 230000002934 lysing Effects 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 210000003519 mature B lymphocyte Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000003340 mental Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate Chemical class CS([O-])(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 230000003278 mimic Effects 0.000 description 1
- 229960000060 monoclonal antibodies Drugs 0.000 description 1
- 102000005614 monoclonal antibodies Human genes 0.000 description 1
- 108010045030 monoclonal antibodies Proteins 0.000 description 1
- 210000002346 musculoskeletal system Anatomy 0.000 description 1
- 230000003505 mutagenic Effects 0.000 description 1
- 231100000219 mutagenic Toxicity 0.000 description 1
- 201000002481 myositis Diseases 0.000 description 1
- 230000001537 neural Effects 0.000 description 1
- 230000003767 neural control Effects 0.000 description 1
- 201000004931 neurofibromatosis Diseases 0.000 description 1
- 230000002314 neuroinflammatory Effects 0.000 description 1
- 230000011242 neutrophil chemotaxis Effects 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000035781 nonspecific defense system Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 230000004650 oncogenic pathway Effects 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 description 1
- 230000001717 pathogenic Effects 0.000 description 1
- 230000003285 pharmacodynamic Effects 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003905 phosphatidylinositols Chemical class 0.000 description 1
- 150000003906 phosphoinositides Chemical class 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000003389 potentiating Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- OZAIFHULBGXAKX-UHFFFAOYSA-N precursor Substances N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000000770 pro-inflamatory Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 150000003814 prostanoids Chemical class 0.000 description 1
- 239000003909 protein kinase inhibitor Substances 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000001105 regulatory Effects 0.000 description 1
- 230000019254 respiratory burst Effects 0.000 description 1
- 200000000008 restenosis Diseases 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- 150000003873 salicylate salts Chemical class 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000036573 scar formation Effects 0.000 description 1
- 201000010208 seminoma Diseases 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000035886 specific defense system Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000012128 staining reagent Substances 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 230000004936 stimulating Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- CIOAGBVUUVVLOB-OUBTZVSYSA-N strontium-89 Chemical compound [89Sr] CIOAGBVUUVVLOB-OUBTZVSYSA-N 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 150000003890 succinate salts Chemical class 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 230000000576 supplementary Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000004083 survival Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002459 sustained Effects 0.000 description 1
- 230000002195 synergetic Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- 229930003347 taxol Natural products 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- NYRDZOBWDHFFBF-UHFFFAOYSA-N tert-butyl N-(9-tritylpurin-6-yl)carbamate Chemical compound C1=NC=2C(NC(=O)OC(C)(C)C)=NC=NC=2N1C(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 NYRDZOBWDHFFBF-UHFFFAOYSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- ZSLUVFAKFWKJRC-UHFFFAOYSA-N thorium Chemical compound [Th] ZSLUVFAKFWKJRC-UHFFFAOYSA-N 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 229940083878 topical for treatment of hemorrhoids and anal fissures Corticosteroids Drugs 0.000 description 1
- 229960000303 topotecan Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 108020003112 toxins Proteins 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N trans-L-hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- LXZZYRPGZAFOLE-UHFFFAOYSA-L transplatin Chemical compound [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H] LXZZYRPGZAFOLE-UHFFFAOYSA-L 0.000 description 1
- 125000005270 trialkylamine group Chemical group 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 201000008100 vaginitis Diseases 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 239000002525 vasculotropin inhibitor Substances 0.000 description 1
- 230000002227 vasoactive Effects 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000017613 viral reproduction Effects 0.000 description 1
- 230000003612 virological Effects 0.000 description 1
- 231100000054 whole-body exposure Toxicity 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- LBDSXVIYZYSRII-IGMARMGPSA-N α-particle Chemical compound [4He+2] LBDSXVIYZYSRII-IGMARMGPSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-QIUUJYRFSA-N β-D-glucuronic acid Chemical compound O[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-QIUUJYRFSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
Abstract
The present invention relates to chromen-4-one derivatives as dual delta (?) and gamma (?) PI3K protein kinase modulators, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of Pi3K kinase mediated diseases or disorders with them. h them.
Description
DUAL IVE PI3 DELTA AND GAMMA KINASE INHIBITORS
[01] The present application claims the benefit of Indian Patent Application Nos.
2501/CHE/2013, filed June 7, 2013, and 5567/CHE/2013, filed December 3, 2013 each of
which is hereby incorporated by reference in its entirety.
FIELD OF THE INVENTION
[02] The present invention provides dual delta (δ) and gamma (γ) PI3K protein kinase
modulators, methods of preparing them, pharmaceutical compositions containing them and
methods of treatment, prevention and/or ration of Pi3K kinase mediated diseases or
disorders with them.
BACKGROUND OF THE INVENTION
[03] Phosphoinositide-3 kinase (PI3K) belongs to a class of intracellular lipid s that
phosphorylate the 3 position hydroxyl group of the inositol ring of phosphoinositide lipids (Pis)
generating lipid second messengers. While alpha and beta isoforms are tous in their
distribution, expression of delta and gamma is restricted to circulating hematogenous cells and
endothelial cells. Unlike PI3K-alpha or beta, mice lacking expression of gamma or delta do not
show any adverse phenotype indicating that targeting of these ic isoforms would not
result in overt toxicity.
[04] Recently, targeted inhibitors of the phosphoinositidekinase (PI3K) pathway have been
suggested as modulatory agents. This interest stems from the fact that the PI3K
pathway serves multiple functions in immune cell signaling, primarily through the tion
of phosphatidylinositol (3,4,5)-trisphosphate (PIP3), a membranebound second messenger .
PIP3 recruits proteins to the cytoplasmic side of the lipid bilayer, including protein kinases and
GTPases, initiating a complex network of downstream signaling es important in the
regulation of immune cell adhesion, migration, and cell-cell communication.
[05] The four class I PI3K ms differ significantly in their tissue distribution. PI3Ka and
ΡΙ3Κβ are ubiquitous and activated ream of receptor tyrosine kinases (RTK), whereas
PI3K δ and PI3K γ are primarily limited to hematopoietic and endothelial cells, and are
ted downstream of RTKs, and G protein coupled receptors (GPCR), respectively. Mouse
genetic studies have revealed that PI3Kα and
1
WO 2014/195888 2014/061954
PI3KB are essential for normal development, whereas loss of PISK 5 andfor PI3K y yields
viable offspring with selective immune deficits.
[06] The expression pattern and functions of PI3K 8 and PI3K V have generated
much interest in developing PI3K5/y tors as agents for many diseases, including
rheumatoid arthritis, allergies, asthma, chronic ctive pulmonary disease and le
sclerosis (Hirsch et al., col. Ther., 118, 192—205, 2008; Marone et al., m
Biophys. Acta., 1784, 159—185, 2008; Rommel et al., Nat. Rev. Immunol, 7, 191—201,
2007; Ruckle et al., Nat. Rev. Drug Discov., 5, 903—918, 2006). Studies using both
pharmacologic and genetic methods have shown these two isoforms often demonstrate
synergistic interactions with each other (Konrad et al., J. Biol. Chem, 283, 33296—33303,
2008; gue et al., Immunity, 16, 441—451, 2002). In mast cells, for example, PI3K5 is
essential for degranulation in response to IgE cross-linking of Fc-receptors (Ali et al., J.
Immunol, 180, 2538—2544, 2008), but PISKy plays an important role in amplifying the
response (Laffargue et al., Immunity, 16, 441—451, 2002). Similar effects have been seen
in other cellular functions, including lymphocyte homing and the neutrophil respiratory
burst where PI3Ky plays a critical role and PI3K5 amplifies each process. The
nonredundant but related roles of PI3K5 and PI3Ky have made it lt to determine
which of the two isoforms (alone or in combination) is best targeted in a particular
inflammatory disorder. Studies using mice that lack PI3K8 and/or PI3Ky or express
kinase—dead variants of PI3K5 and PI3Ky have been valuable tools in understanding their
roles. For example, PI3K8 knockout mice demonstrated diminished neutrophil chemotaxis,
diminished antibody production (both T cell dependent and independent) (Jou et al., Moi.
Cell.Biol., 22, 591, 2002), and lower numbers of mature B cells (Clayton et al., J.
Exp. Med, 196, 3, 2002; Jou er al., Mal. iol., 22, 8580—8591, 2002), and a
decrease in their proliferation in response to anti-IgM (Jou et al., 2002) . This phenotype
was replicated in the PI3K5 kinase-dead variant and with PI3K6 ive tors along
with decreased numbers of and proliferation of mast cells, and an attenuated allergic
response. The P13Ky knockout contained higher numbers of, but less responsive,
neutrophils, lower numbers of and less responsive macrophages and dendritic cells
displayed decreased mast cell degranulation (Laffargue et al., 2002), a higher ratio of
CD4+ to CD8+ T cells), increased yte apoptosis, diminished induction of CXCR3
on activated T cells and decreased c contractility. This latter effect on cardiac tissue
was a concern for chronic dosing of patients with PI3K7 inhibitors. However, this concern
was largely mitigated when the PI3Ky kinase-dead variant (which better mimics inhibition
of the kinase rather than loss of the protein) showed similar immune cell phenotypes, but
2
WO 2014/195888 2014/061954
importantly had no cardiac defects. The cardiac effect was later shown to be due to
lding effects rather than the catalytic activity of PI3Ky. The dual PI3K5/PI3Ky
knockout was viable but exhibited serious defects in T cell development and thymocyte
survival. The PI3Ky knockout/PBKS kinase-dead combination produced a similar
phenotype suggesting that at least within the immune system, the role of PI3K8 is likely
only a catalytic one. Interpretation of studies using knockout and kinase-dead mice can be
challenging because these models provide only a steady-state picture of the immune
system, lack temporal and dose control, and do not permit a full understanding of how a
dynamic immune response will react to reversible inhibition. Selective inhibitors with
varying profiles (PI3K5, PI3Ky, and PI3K5/y) are ary for studies of yte
signaling in order to assess the relative contributions of each PI3K to immune cell
activation gon et al., try & Biology, 1, 123-134 (2010), including the
references cited )
[07] Dual inhibition of 5/y is strongly implicated as an intervention strategy in
allergic and lergic inflammation of the airways and other autoimmune diseases.
Scientific evidence for PI3K-8 and y gamma involvement in various cellular processes
underlying asthma and COPD stems from tor studies and gene-targeting approaches.
Also, resistance to conventional therapies such as corticosteroids in several COPD ts
has been attributed to an up-regulation of the PI3K S/y pathway. Disruption of PI3K- S/y
signalling ore es a novel strategy aimed at counteracting the immuno—
inflammatory response. Due to the pivotal role played by PI3K- 5 and y in mediating
inflammatory cell functionality such as leukocyte migration and activation, and mast cell
degranulation, blocking these isoforms may also be an effective strategy for the treatment
of rheumatoid arthritis as well. Given the established criticality of these isoforms in
immune surveillance, inhibitors specifically ing the 5 and y isoforms would be
expected to attenuate the progression of immune se encountered in airway
inflammation and rheumatoid arthritis (William et.al Chemistry & Biology, 17, 4,
2010 and Thompson, et al. Chemistry & Biology, 17:101—102, 2010)
[08] Reviews and studies regarding PI3K and related protein kinase pathways
have been given by Liu et. al., Nature Reviews Drug Discovery, 8, 627-644, 2009); Nathan
T. et. al., Mol Cancer Ther., 8(1), 2009; Marone et, al., Biochimica et Biophysica Acta,
1784, 159-185, 2008 and Markman et. al., Annals of Oncology Advance Access, published
August 2009. Similarly s and studies regarding role of PI3K 5 and V have been
given by William et.al., Chemistry & Biology, 17, 123-134, 2010 and Timothy et.al. J.
WO 2014/195888 PCT/IB2014/061954
Med. Chem, 55 (20), 8559—8581,2012. All of these literature disclosures are hereby
incorporated by reference in their entirety.
[09] Compounds such as 5 and CAL130 have been reported as dual
inhibitors of Pi3K 5/7. 5 is under clinical investigation for cancer, asthma and
rheumatoid arthiritis. IPI-45 have been ed to have a maximum tolerated dose (MTD)
of 75 mg BID (55th ASH® Annula Meeting New Orleans-LA, Dec 7-10, 2013). There are
no reports of CAL-130 being investigated for clinical purposes.
[10] There still remains an unmet need for dual 5 y PI3K modulators for the
treatment of es and disorders associated with S/y PI3K kinases-mediated events.
[11] Further reference is made herein to International ation Nos. WO
11/055215 and WO 12/151525 and US. Publication Nos. 2011/0118257 and
2012/0289496, each of which is incorporated herein by reference in its entirety.
SUMMARY OF THE INVENTION
[12] The present invention is directed to selective dual inhibitors of PI3K delta
and gamma protein kinases. These compounds are suitable for use in a pharmaceutical
composition for the treatment of a PI3K associated disease, disorder or condition, e.g., a
proliferative disease such as cancer. Inhibition of both PI3K delta and gamma protein
kinases may provide cial effects in the treatment of certain diseases and disorders.
[13] The selective dual inhibitors of the t invention include the following
compounds, pharmaceutically acceptable salts f, and prodrugs thereof:
(RS)—2-(1-(9H-purin-6—ylamino)propy1)-3—(3-fluorophenyl)-4H—chromen—4-one.
(Compound A)
(S)-2—(1-(9H—purin-6—ylamino)propyl)—3-(3-fluorophenyl)-4H-chromen-4—one.
und A1)
(R)-2—(1-(9H—purin-6—ylamino)propyl)—3-(3-fluorophenyl)-4H-chromen-4—one.
(Compound A2)
[14] The chemical structures of the compounds of the t invention are
shown below.
WO 2014/195888 PCT/IB2014/061954
(A) (A1) (A2)
[15] In one embodiment, the present invention relates to the compound (S)(1—
(9H-purinylamino)propyl)-3—(3-fluorophenyl)-4H-chromenone, or a
pharmaceutically acceptable salt thereof.
[16] In one embodiment, the compound (S)-2—(l-(9H-purinylamino)propyl)-
3-(3-fluorophenyl)-4H-chromenone, or a pharmaceutically acceptable salt thereof, is
substantially free (e.g., contains less than about 10%, such as less than about 5%, less than
about 2.5%, less than about 1%, less than about 0.1% by weight or is free) of (1—
(9H-puriny1amino)propyl)-3—(3-fluorophenyl)—4H-chromenone and pharmaceutically
acceptable salts f.
[17] In r embodiment, the compound (l-(9H—purin-6—
ylamino)propyl)(3—fluorophenyl)-4H—chromenone, or a pharmaceutically acceptable
salt thereof, has an enantiomeric excess of greater than about 90%, such as greater than
about 91%, greater than about 92%, greater than about 93%, greater than about 94%,
greater than about 95%, greater than about 96%, greater than about 97%, greater than
about 98%, r than about 99%, greater than about 99.5%, greater than about 99.9%,
or greater than about 99.99%.
[18] In one preferred embodiment, the present invention relates to the compound
(S)(l-(9H-purinylamino)propyl)-3—(3-fluorophenyl)—4H-chromen-4—one (Compound
Al).
[19] The invention further provides a ceutical composition comprising
one or more compounds of the t invention (such as compound Al) together with a
pharmaceutically acceptable carrier. The pharmaceutical composition may further
comprise one or more of additional active agents (such as anti-cancer agents and the active
agents discussed below). In one ment, the pharmaceutical composition includes a
therapeutically effective amount of one or more compounds of the present invention.
WO 2014/195888 PCT/IB2014/061954
[20] r embodiment is a method of inhibiting PI3K delta and gamma in a
patient by administering to the patient an effective amount of at least one compound of the
present invention.
[21] Yet another embodiment is a method of treating, preventing, and/or
inhibiting a PI3K protein kinase mediated disease, disorder or condition (such as cancer or
other proliferative disease or disorder) in a patient by administering to the patient an
effective amount of at least one nd of the present ion.
[22] Yet another embodiment of the present invention is a method for inhibiting
PI3K, in particular PI3K delta and gamma kinase in a t by administering to the
patient an effective amount of at least one compound of the present invention.
[23] Yet another embodiment of the present ion is a method for treating an
inflammatory, autoimmune or proliferative e via tion of a protein kinase
(such as P13 delta and gamma kinase) by administering to a patient in need of such
treatment an effective amount of at least one compound of the present ion. In one
embodiment, the compound of the present invention inhibits both the PI3K delta and
gamma protein kinase.
[24] Yet another embodiment of the present invention is a method for treating an
inflammatory, autoimmune or proliferative disease via modulation of a protein kinase
(such as P13 delta and gamma kinase) by administering to a patient in need of such
ent an effective amount of at least one nd of the present invention, in
combination (simultaneously or sequentially) with at least one other anti-inflammatory,
immunomodulator or anti-cancer agent (or a combination thereof). In one ment, the
compound of the present ion inhibits both the PI3K delta and gamma protein kinase.
[25] The compounds of the present invention are useful in the treatment of a
variety of cancers, including, but not limited to:
[26] carcinoma, including, but not limited to, that of the bladder, breast, colon,
kidney, liver, lung, including small cell lung , esophagus, gall bladder, ovary,
pancreas, stomach, cervix, thyroid, prostate, and skin, including squamous cell carcinoma;
[27] hematopoietic tumors of lymphoid lineage, including, but not limited to,
leukemia, acute lymphocytic leukemia, acute lymphoblastic leukemia, B—cell lymphoma,
T-cell lymphoma, Hodgkin's lymphoma, non-Hodgkins lymphoma, hairy cell lymphoma
and Burkett's lymphoma;
[28] hematopoietic tumors of myeloid lineage, including, but not limited to,
acute and c myelogenous leukemias, myelodysplastic me and promyelocytic
leukemia;
WO 2014/195888 PCT/IB2014/061954
[29] tumors of mesenchymal origin, including, but not limited to, fibrosarcoma
and rhabdomyosarcoma;
[30] tumors of the central and peripheral nervous system, including, but not
limited to, ytoma, neuroblastoma, glioma and schwannomas; and
[31] other tumors, including, but not d to, melanoma, seminoma,
teratocarcinoma, osteosarcoma, xenoderoma pigmentosum, keratoctanthoma, thyroid
follicular cancer and Kaposi's sarcoma.
[32] In one emobodiment, the compounds of the present invention are
administered to treat a leukemia, acute lymphocytic leukemia, acute lymphoblastic
leukemia, B-cell lymphoma, T-cell ma, Hodgkin's lymphoma, non-Hodgkins
lymphoma, hairy cell lymphoma, Burkett's lymphoma, acute and chronic myelogenous
leukemias, myelodysplastic syndrome and promyelocytic leukemia.
[33] Due to the key role of protein kinases in the regulation of ar
proliferation in general, the protein kinase inhibitors of the present invention could act as
reversible cytostatic agents, and may be useful therefore in the treatment of any e
process which features abnormal cellular proliferation, e. g., benign prostatic lasia,
familial adenomatosis polyposis, neuro-fibromatosis, atherosclerosis, pulmonary fibrosis,
arthritis, psoriasis, glomerulonephritis, restenosis following lasty or vascular
y, hypertrophic scar formation, inflammatory bowel disease, transplantation
ion, xic shock, and fungal ions.
[34] The compounds of the t invention as modulators of apoptosis are
useful in the treatment of cancer (including but not limited to those types mentioned herein
above), viral infections (including, but not limited to, herpevirus, poxvirus, Epstein-Barr
Virus, Sindbis virus and adenovirus), autoimmune es (including, but not limited, to
systemic lupus, erythematosus, mune ed glomerulonephritis, rheumatoid
arthritis, psoriasis, inflammatory bowel disease, and autoimmune diabetes mellitus),
neurodegenerative disorders (including, but not limited to, Alzheimer's disease, AIDS—
related dementia, Parkinson's disease, amyotrophic lateral sclerosis, retinitis pigmentosa,
spinal muscular atrophy and cerebellar degeneration), myelodysplastic syndromes, ic
anemia, ischemic injury associated with myocardial infarctions, stroke and reperfusion
injury, arrhythmia, atherosclerosis, toxin-induced or alcohol related liver diseases,
hematological diseases (including, but not limited to, chronic anemia and aplastic anemia),
degenerative diseases of the musculoskeletal system (including, but not d to,
osteoporosis and arthritis) aspirin-sensitive rhinosinusitis, cystic fibrosis, multiple
sclerosis, kidney diseases and cancer pain. The compounds of the present invention are
7
WO 2014/195888 PCT/IB2014/061954
also useful in the prevention, tion, or suppression of AIDS development in HIV-
infected duals.
[35] The compounds of the t invention can modulate the level of cellular
RNA and DNA sis. These agents are therefore useful in the treatment of viral
ions, including, but not limited to, HIV, human papilloma virus, herpesvirus,
poxvirus, Epstein-Barr virus, Sindbis virus and adenovirus.
[36] The compounds of the present invention are useful in the chemoprevention
of cancer. Chemoprevention is d as inhibiting the development of invasive cancer by
either blocking the initiating mutagenic event or by blocking the progression of pre-
malignant cells that have already suffered an insult or inhibiting tumor relapse. The
compounds of the present invention are also useful in inhibiting tumor angiogenesis and
metastasis. One embodiment of the invention is a method of inhibiting tumor angiogenesis
or metastasis in a patient in need thereof by administering an effective amount of one or
more compounds of the present invention.
[37] Another embodiment of the present invention is a method of treating an
immune system-related disease (e.g., an mune disease), a disease or disorder
involving inflammation (e.g., asthma, chronic obstructive pulmonary disease (COPD),
rheumatoid arthritis, inflammatory bowel disease, glomerulonephritis, neuroinflammatory
diseases, multiple sclerosis, uveitis and disorders of the immune system), cancer or other
proliferative disease, a c disease or disorder, a renal disease or disorder. The method
includes administering an effective amount of one or more compounds of the present
invention.
[38] Examples of immune disorders include, but are not limited to, psoriasis,
rheumatoid arthritis, vasculitis, inflammatory bowel disease, dermatitis, osteoarthritis,
, inflammatory muscle disease, allergic rhinitis, vaginitis, interstitial is,
scleroderma, osteoporosis, , allogeneic or xenogeneic transplantation (organ, bone
marrow, stem cells and other cells and tissues) graft rejection, versus-host disease,
lupus erythematosus, inflammatory disease, type I diabetes, pulmonary fibrosis,
dermatomyositis, Sjogren's syndrome, thyroiditis (e.g., Hashimoto's and autoimmune
thyroiditis), myasthenia gravis, autoimmune hemolytic anemia, multiple sclerosis, cystic
fibrosis, chronic relapsing hepatitis, primary biliary sis, allergic ctivitis and
atopic dermatitis.
[39] In one embodiment, the nds described herein are useful as
immunosuppresants to prevent transplant graft rejections, allogeneic or xenogeneic
transplantation rejection (organ, bone marrow, stem cells, other cells and tissues), and graft
WO 2014/195888 PCT/IB2014/061954
- versus - host disease. In other embodiments, transplant graft rejections result from tissue
or organ transplants. In further embodiments, graft-versus-host disease results from bone
marrow or stem cell transplantation. One ment is a method of preventing or
sing the risk of transplant graft rejection, allogeneic or xenogeneic transplantation
rejection (organ, bone marrow, stem cells, other cells and s), or graft - versus - host
disease by administering an effective amount of one or more compounds of the present
invention.
[40] The compounds of the present invention are also useful in combination
(administered er or sequentially) with known anti-cancer treatments, such as
radiation therapy or with cytostatic or cytotoxic or anticancer , such as, for e,
DNA interactive , such as cisplatin or doxorubicin; topoisomerase II inhibitors, such
as etoposide; topoisomerase I tors such as CPT-ll or topotecan; tubulin interacting
agents, such as paclitaxel, docetaxel or the epothilones (for e ixabepilone), either
naturally occurring or synthetic; al agents, such as tamoxifen; thymidilate synthase
inhibitors, such as 5—fluorouracil; and anti—metabolites, such as rexate, other
tyrosine kinase tors such as Iressa and OSI-774; angiogenesis inhibitors; EGF
inhibitors; VEGF inhibitors; CDK inhibitors; SRC inhibitors; c-Kit inhibitors; Herl/2
inhibitors and monoclonal antibodies ed against growth factor receptors such as
erbitux (EGF) and herceptin (Her2) and other protein kinase modulators as well.
[41] The compounds of the present invention are also useful in combination
(administered together or sequentially) with one or more steroidal anti-inflammatory
drugs, non-steroidal anti-inflammatory drugs (NSAIDs) or immune selective anti—
inflammatory derivatives (ImSAIDs).
[42] The invention further provides a pharmaceutical composition comprising
one or more compounds of the present invention together with a pharmaceutically
acceptable carrier. The pharmaceutical composition may further comprise one or more of
the active ingredients identified above, such as other ancer agents.
[43] Yet another embodiment is a method of treating leukemia in a patient in
need thereof by administering a therapeutically effective amount of a compound of the
present invention. For example, the compounds of the present invention are ive for
treating chronic lymphocytic ia (CLL), non-Hodgkin lymphoma (NHL), Hodgkin
lymphoma (HL) acute myeloid leukemia (AML), multiple a (MM), small
lymphocytic lymphoma (SLL), and indolent non-Hodgkin’s lymphoma (I-NHL).
[44] Yet another embodiment is a method of treating leukemia in a patient in
need thereof by administering a therapeutically effective amount of a compound of the
9
WO 2014/195888 PCT/IB2014/061954
t invention. For e, the compounds of the present invention are effective for
treating autoimmune disorders such as asthma, COPD, rhematoid arthritis, psorias, lupus
and experimental mune encephalomyelitis (EAE).
[45] Yet r embodiment is a method of treating allergic rhinitis in a patient
in need thereof by administering a therapeutically effective amount of a compound of the
present invention.
BRIEF DESCRIPTION OF THE DRAWINGS
BRIEF DESCRIPTION OF THE DRAWINGS
[46] Figure 1 depicts a bar graph of the neutrophil count in bronchoalveolar
lavage fluid (BALF) from animals treated with 0, 0.3, 1, 3, and 10 mgikg of Compound
A1 (p0) according to the Lipopolysaccharide d pulmonary neutrophilia model
described in Assay 7.
[47] Figure 2 depicts a bar graph of the neutrophil count in neal lavage
fluid from animals treated with 0, 1, 3, and 10 mg/kg of Compound A1 (p0) according to
the Lipopolysaccharide—induced rat air pouch inflammation model described in Assay 8.
[48] Figure 3 depicts a bar graph of the Lipopolysaccharide-induced plasma
TNF-(x concentration in fasted female Wistar rats following administration of 0, 1, 3, and
10 mg/kg of Compound A1 (p0) according to the procedure described in Assay 9.
[49] Figures 4A and 4B depict graphs of enhanced pause (Penh) or PEF/PIF
(peak expiratory flow / peak inspiratory flow) ratio, tively, in sensitized male guinea
pigs following methacholine challenge and treatment with OVA/SAL or OVA/OVA or
0.3, 1, or 3 mgfkg Compound A1 according to the procedure in Assay 10A.
[50] Figures 4C-4E depict bar graphs of eosinophil count in BALF, total cell
count in BALF, and tage eosinophils, respectively, in min-sensitized male
guinea pigs and treatment with 0, 0.3, 1, or 3 mg/kg Compound A1 according to the
procedure in Assay 10A.
[51] Figures 5A and 5B depict graphs of Penh) or PEF/PIF ratio, respectively, in
ovalbumin-sensitized mice following methacholine challenge and treatment with
SAL/SAL, L or OVA/OVA or 3 mg/kg Compound A1 according to the
procedure in Assay 10B.
[52] Figures SC-SE depict bar graphs of eosinophil count in BALF, total cell
count in BALF, and percentage eosinophils, respectively, in ovalbumin-sensitized mice
and treated with 0 or 3 mg/kg Compound A1 according to the procedure in Assay 10B.
10
WO 95888 PCT/IB2014/061954
[53] Figures 6A and 6B depict bar graphs of individual histopathological scores
for ankle and knee, respectively, in collagen induced arthritis using Lewis rats treated with
a control or 15 mg/kg/BID of compound A1 according to the procedure in Assay 11.
[54] Figures 6C and 6D depict bar graphs of summed histopathological scores
for ankle and knee, tively, in collagen induced arthritis model using Lewis rats
treated with vehicle or 15 mg/kg/BID of compound A1 according to the procedure in
Assay 11.
[55] s 7A and 7B depict bar graphs of macrophage and neutrophil cell
counts, respectively, in BALF following administration of 0.3, 1, or 3 mg/kg/BID of
Compound A1 in male Balb/c mice in a cigarette smoke induced cell ration model as
described in Assay 15.
[56] Figure 8 depicts a graph showing the inhibition of AKT phosphorylation in
leukemic cell lines (MOLT-4, Jurkat, CCRF-CEM, Hut—78, and HuT-102) by Compound
A1 according to the procedure in Assay 3.
[57] Figure 9 depicts a graph showing the inhibition in tage of CD63
positive cells induced by fMLP or anti—FcaRl in human whole blood by Compound A1
according to the procedure in Assay 4.
[58] Figure 10 depicts a graph showing the inhibition of anti-human CD3/CD28—
induced cytokines (TNFa, IFNy and IL2) by Compound A1 according to Assay 6D.
DETAILED DESCRIPTION OF THE INVENTION
[59] As used herein the following definitions shall apply unless otherwise
ted. Further many of the groups defined herein can be optionally tuted. The
g of substituents in the definition is exemplary and is not to be construed to limit the
substituents d elsewhere in the specification.
[60] Certain of the compounds described herein contain one or more asymmetric
centers and can thus give rise to enantiomers, diastereomers, and other stereoisomeric
forms that can be defined, in terms of absolute stereochemistry, as (R)— or (S)—. Unless
otherwise ied, the present chemical entities, pharmaceutical compositions and
methods are meant to include all such possible isomers, including racemic mixtures,
optically pure forms and intermediate mixtures. For the instance, non-limiting example of
intermediate mixutures include a mixture of R:S or S:R isomers in a ratio of 10:90, 13:87,
17:83, 20:80, or 22:78. Optically active (R)- and (S)- isomers can be prepared using chiral
synthons or chiral reagents, or resolved using conventional techniques. When the
nds described herein n ic double bonds or other s of geometric
11
WO 95888 PCT/IB2014/061954
asymmetry, and unless specified otherwise, it is intended that the compounds include both
E and Z geometric isomers.
[61] The term "tautomers" refers to compounds, which are characterized by
relatively easy interconversion of ic forms in equilibrium. These isomers are
intended to be covered by this invention. "Tautomers" are structurally ct isomers that
interconvert by tautomerization. "Tautomerization" is a form of ization and includes
prototropic or proton-shift tautomerization, which is considered a subset of acid-base
chemistry. "Prototropic tautomerization" or "proton-shift tautomerization" involves the
migration of a proton accompanied by changes in bond order, often the hange of a
single bond with an adjacent double bond. Where tautomerization is possible (e.g. in
solution), a chemical equilibrium of ers can be d. An example of
tautomerization is keto-enol tautomerization. A specific example of keto-enol
tautomerization is the interconversion of pentane-2,4-dione and 4-hydroxypent-3—enone
tautomers. Another example of tautomerization is phenol-keto tautomerization. A specific
example of phenol-keto tautomerization is the interconversion of pyridin—4-ol and pyridin—
4(1H)—one tautomers.
[62] The term "prodrug" refers to a compound, which is an inactive precursor of
a compound that is converted into its active form in the body by normal metabolic
processes. g design is sed generally in Hardma, et al. (Eds.), Goodman and
Gilman's The Pharmacological Basis of Therapeutics, 9th ed., pp. 11-16 (1996). A
thorough discussion is provided in Higuchi, et al., Prodrugs as Novel Delivery Systems,
Vol. 14, ASCD Symposium , and in Roche (ed.), Bioreversible Carriers in Drug
Design, American Pharmaceutical Association and Pergamon Press (1987). To illustrate,
prodrugs can be converted into a pharmacologically active form through hydrolysis of, for
example, an ester or amide linkage, y introducing or exposing a functional group on
the resultant product. The gs can be designed to react with an nous
compound to form a water-soluble conjugate that further enhances the pharmacological
properties of the compound, for example, increased circulatory half-life. Alternatively,
gs can be designed to undergo covalent modification on a functional group with, for
e, glucuronic acid, sulfate, glutathione, amino acids, or e. The resulting
conjugate can be inactivated and excreted in the urine, or rendered more potent than the
parent compound. High molecular weight conjugates also can be excreted into the bile,
subjected to enzymatic cleavage, and released back into the circulation, thereby effectively
increasing the biological half-life of the originally administered compound.
12
WO 2014/195888 PCT/IB2014/061954
[63] The term "ester" refers to a compound, which is formed by reaction
between an acid and an l with elimination of water. An ester can be ented by
the general formula RCOOR' (where R is a drug and R’ is a chemical group).
[64] These prodrugs and esters are intended to be covered within the scope of
this invention.
[65] Additionally the instant invention also includes the compounds which differ
only in the presence of one or more isotopically enriched atoms for example replacement
of hydrogen with deuterium or tritium, or the ement of a carbon by 13C— or 14C-
enriched carbon.
[66] The compounds of the present invention may also contain unnatural
proportions of atomic es at one or more of atoms that constitute such compounds.
For e, the compounds may be radiolabeled with radioactive isotopes, such as for
example tritium (3H), iodine—125 (1251) or carbon-l4 (14C). All isotopic variations of the
compounds of the present invention, whether radioactive or not, are encompassed within
the scope of the present invention.
[67] Pharmaceutically acceptable salts forming part of this invention e
salts derived from inorganic bases such as Li, Na, K, Ca, Mg, Fe, Cu, Zn, and Mn; salts of
organic bases such as N,N'-diacetylethylenediamine, glucamine, ylamine, choline,
hydroxide, dicyclohexylamine, metformin, benzylamine, trialkylamine, and thiamine;
chiral bases such as henylamine, glycinol, and phenyl glycinol; salts of natural
amino acids such as glycine, alanine, valine, leucine, isoleucine, norleucine, tyrosine,
cystine, cysteine, methionine, proline, hydroxy proline, histidine, omithine, lysine,
arginine, and serine; quaternary ammonium salts of the compounds of invention with alkyl
s, alkyl tes such as Mel and (Me)ZSO4; non-natural amino acids such as D—
isomers or substituted amino acids; ine; and substituted guanidine n the
substituents are selected from nitro, amino, alkyl, alkenyl, l, ammonium or
tuted ammonium salts and aluminum salts. Salts may include acid addition salts
where appropriate which may be sulphates, nitrates, phosphates, perchlorates, borates,
hydrohalides, es, tartrates, maleates, citrates, fumarates, succinates, palmoates,
methanesulphonates, benzoates, salicylates, benzenesulfonates, ascorbates,
glycerophosphates, and ketoglutarates.
[68] When ranges are used herein for physical properties, such as molecular
weight, or chemical properties, such as al formulae, all combinations and
subcombinations of ranges and specific embodiments therein are intended to be included.
The term "about" when referring to a number or a numerical range means that the number
13
WO 2014/195888 PCT/IB2014/061954
or numerical range referred to is an approximation within mental variability (or
within statistical experimental error), and thus the number or numerical range may vary
from, for example, between 1% and 15% of the stated number or numerical range. The
term "comprising" (and d terms such as ise" or "comprises" or "having" or
"including") includes those embodiments, for example, an embodiment of any composition
of matter, composition, , or process, or the like, that "consist of” or "consist
essentially of” the described features.
[69] The ing abbreviations and terms have the indicated meanings
throughout: PI3-K = Phosphoinositide 3-kinase; PI = phosphatidylinositol; AIDS =
Acquired Immuno Deficiency Syndrome; HIV = Human Immunodeficiency Virus; MeI =
Methyl Iodide; ND: Not determined.
[70] Abbreviations used herein have their conventional meaning within the
al and biological arts.
[71] The term "cell proliferation" refers to a phenomenon by which the cell
number has changed as a result of division. This term also encompasses cell growth by
which the cell morphology has changed (e.g., increased in size) consistent with a
proliferative signal.
[72] The terms "co-administration, II II administered in ation with," and
their grammatical equivalents, as used herein, encompass administration of two or more
agents to an animal so that both agents and/or their metabolites are present in the animal at
the same time. Co-administration includes simultaneous administration in separate
compositions, stration at different times in separate compositions, or administration
in a composition in which both agents are present.
[73] The term tive amount" or "therapeutically effective amount" refers to
that amount of a compound bed herein that is ient to effect the intended
application including but not limited to disease treatment, as defined below. The
therapeutically effective amount may vary depending upon the intended application (in
vitro or in vivo), or the subject and disease condition being treated, e. g., the weight and age
of the subject, the severity of the disease condition, the manner of administration and the
like, which can y be determined by one of ordinary skill in the art. The term also
applies to a dose that will induce a particular response in target cells, e.g. ion of
et adhesion andi'or cell migration. The specific dose will vary depending on the
particular compounds chosen, the dosing regimen to be followed, whether it is
administered in combination with other compounds, timing of administration, the tissue to
which it is administered, and the physical delivery system in which it is carried.
14
WO 2014/195888 PCT/IB2014/061954
[74] As used herein, "treatment," ing," or "ameliorating" are used
interchangeably. These terms refers to an approach for obtaining beneficial or d
results including but, not d to, therapeutic benefit and/or a lactic benefit. By
therapeutic benefit is meant eradication or amelioration of the underlying disorder being
treated. Also, a therapeutic benefit is ed with the eradication or amelioration of one
or more of the physiological symptoms associated with the underlying disorder such that
an improvement is observed in the patient, notwithstanding that the patient may still be
afflicted with the underlying disorder. For prophylactic benefit, the compositions may be
administered to a patient at risk of ping a particular disease, or to a patient ing
one or more of the physiological symptoms of a disease, even though a diagnosis of this
e may not have been made.
[75] A "therapeutic effect," as that term is used herein, encompasses a
therapeutic benefit andfor a lactic benefit as described above. A prophylactic effect
includes delaying or eliminating the ance of a disease or condition, delaying or
eliminating the onset of symptoms of a disease or condition, slowing, halting, or reversing
the progression of a disease or condition, or any combination thereof.
[76] The term "subject" or “patient” refers to an animal (e. g., a dog, cat, horse,
or pig), such as a , for example a human. The methods described herein can be
useful in both human therapeutics and veterinary applications. In some embodiments, the
patient is a mammal, and in some embodiments, the patient is human.
[77] "Radiation y" means exposing a patient, using routine methods and
compositions known to the practitioner, to radiation emitters such as alpha—particle
emitting uclides (e.g., actinium and thorium radionuclides), low linear energy
transfer (LET) radiation emitters (i.e. beta emitters), conversion electron emitters (e.g.
strontium-89 and samarium- lS3—EDTMP), or high-energy radiation, including, without
limitation, x-rays, gamma rays, and neutrons.
[78] l transduction" is a process during which stimulatory or inhibitory
signals are itted into and within a cell to elicit an intracellular response. A
tor of a signal transduction pathway refers to a compound which modulates the
activity of one or more cellular proteins mapped to the same specific signal transduction
pathway. A modulator may augment (agonist) or suppress (antagonist) the activity of a
signaling molecule.
[79] The term "selective inhibition" or "selectively inhibit" as applied to a
biologically active agent refers to the agent's ability to selectively reduce the target
15
WO 2014/195888 PCT/IB2014/061954
signaling activity as compared to off—target signaling activity, via direct or indirect
interaction with the target.
[80] The term "pharmaceutically able carrier" or "pharmaceutically
acceptable excipient" includes, but is not limited to, any and all solvents, dispersion media,
coatings, antibacterial and antifungal agents, isotonic and absorption delaying , one
or more suitable diluents, s, salts, disintegrants, binders, lubricants, glidants, wetting
agents, controlled release matrices, colorants/flavoring, carriers, excipients, buffers,
stabilizers, solubilizers, and combinations thereof. Except insofar as any conventional
media or agent is incompatible with the active ingredient, its use in the therapeutic
itions of the invention is contemplated. Supplementary active ingredients can also
be incorporated into the compositions.
[81] In certain embodiments, one or more of the compounds described herein
bind specifically to a P13 kinase or a protein kinase selected from the group consisting of
mTor, DNA-dependent n kinase (Pubmed protein accession number (PPAN)
AAA79184), AbI tyrosine kinase (CAA52387), Bcr-Abl, hemopoietic cell kinase (PPAN
CA119695), Src (PPAN CAA24495), vascular endothelial growth factor receptor 2 (PPAN
19), epidermal growth factor or (PPAN AG43241), EPH receptor B4
(PPAN EAL23820), stem cell factor receptor (PPAN AAF22141), Tyrosine-protein kinase
receptor TIE—2 (PPAN Q02858), lated tyrosine kinase 3 (PPAN l 10),
platelet-derived growth factor receptor alpha (PPAN NP_990080), RET (PPAN
CAA73l3l), and any other related n kinases, as well as any onal mutants
thereof.
[82] In other embodiments, the 1C50 of a compound described herein for pi 10a,
pi lOB, pi 107, or pi 105 is less than about 1 uM, less than about 100 nM, less than about
50 nM, less than about 10 nM, less than 1 nM or less than about 0.5nM. In some
embodiments, the 1C50 of a compound described herein for mTor is less than about 1 uM,
less than about 100 nM, less than about 50 nM, less than about 10 nM, less than 1 nM or
less than about 0.5nM. In some other embodiments, one or more of the compounds
described herein exhibit dual binding specificity and are capable of inhibiting a PI3 kinase
(e.g., a class I P13 kinase) as well as a protein kinase (e.g., mTor) with an 1C50 value less
than about 1 uM, less than about 100 nM, less than about 50 nM, less than about 10 nM,
less than 1 nM or less than about 0.5 nM.
[83] In additional embodiments, the compounds of the present invention exhibit
one or more functional characteristics disclosed . For e, one or more of the
compounds described herein bind specifically to a PI3 kinase. In some embodiments, the
16
WO 2014/195888 PCT/IB2014/061954
IC50 of a nd described herein for pi 10a, pi 10B, pi 10y, or pi 105 is less than about
1 uM, less than about 100 nM, less than about 50 nM, less than about 10 nM, less than
about 1 nM, less than about 0.5nM, less than about 100pM, or less than about 50 pM.
[84] In other embodiments, the compounds of the present invention selectively
inhibit one or more members of type I or class I phosphatidylinositol 3-kinases (P13-
) with an IC50 value of about 100 nM or less, about 50 nM or less, about 10 nM or
less, about 5 nM or less, about 100 pM or less, about 10 pM or less, or about 1 pM or less
as measured in an in vitro kinase assay.
[85] In yet r , an tor that selectively inhibits one or more
members of type I PI3—kinases, or an tor that selectively inhibits one or more type I
PI3—kinase mediated signaling pathways, alternatively can be understood to refer to a
compound that exhibits a 50% inhibitory concentration (IC50) with respect to a given type I
PI3—kinase, that is at least 10—fold lower, at least 20-fold lower, at least 50-fold lower, at
least 100-fold lower, at least lOOO-fold lower than the inhibitor's IC50 with respect to the
rest of the other type I P13 -kinases.
[86] As used herein, the term “dual PI3-kinase 5 / y inhibitor" and “dual PI3—
kinase 5 / y selective inhibitor” refers to a compound that inhibits the activity of both the
PI3-kinase 5 and y isozyme more effectively than other isozymes of the PI3K family. A
dual PI3-kinase 5 / y inhibitor is therefore more selective for PI3-kinase 5 and y than
conventional PI3K tors such as CAL-130, wortmannin and LY294002, which are
nonselective PI3K inhibitors.
[87] Inhibition of PI3—kinase 5 and 7 may be of therapeutic benefit in treatment
of various conditions, e. g., conditions characterized by an inflammatory response
including, but not limited to, autoimmune es, ic diseases, and arthritic diseases.
Importantly, inhibition of PI3-kinase 8 and y function does not appear to affect ical
functions such as viability and fertility.
[88] "Inflammatory response" as used herein is characterized by redness, heat,
swelling and pain (i.e., inflammation) and typically involves tissue injury or destruction.
An inflammatory response is usually a localized, tive response elicited by injury or
destruction of tissues, which serves to destroy, dilute or wall off (sequester) both the
injurious agent and the injured tissue. Inflammatory responses are notably associated with
the influx of leukocytes and/or leukocyte (e.g., neutrophil) chemotaxis. Inflammatory
responses may result from infection with pathogenic organisms and Viruses, noninfectious
means such as trauma or reperfusion following myocardial infarction or stroke, immune
responses to foreign ns, and autoimmune diseases. Inflammatory responses
17
WO 2014/195888 PCT/IB2014/061954
amenable to treatment with the methods and compounds according to the invention
encompass conditions associated with reactions of the specific defense system as well as
conditions associated with reactions of the non-specific defense system.
[89] The therapeutic methods of the invention include methods for the
amelioration of conditions associated with atory cell activation. "Inflammatory
cell activation" refers to the induction by a stimulus (including but not d to,
cytokines, antigens or auto-antibodies) of a proliferative cellular response, the production
of soluble mediators (including but not limited to cytokines, oxygen radicals, enzymes,
prostanoids, or vasoactive ), or cell surface expression of new or increased numbers
of mediators (including but not limited to, major histocompatibility antigens or cell
adhesion molecules) in inflammatory cells (including but not limited to monocytes,
macrophages, T lymphocytes, B lymphocytes, ocytes (polymorphonuclear
leukocytes including neutrophils, ils, and eosinophils) mast cells, dendritic cells,
Langerhans cells, and endothelial cells). It will be appreciated by persons d in the art
that the activation of one or a combination of these phenotypes in these cells can contribute
to the initiation, perpetuation, or exacerbation of an inflammatory ion.
[90] "Autoimmune disease" as used herein refers to any group of disorders in
which tissue injury is associated with humoral or cell-mediated responses to the body's
own constituents.
[91] "Transplant rejection" as used herein refers-to any immune response
directed against d tissue (including organs or cells (e. g., bone marrow), characterized
by a loss of function of the grafted and surrounding tissues, pain, swelling, leukocytosis,
and thrombocytopenia).
[92] "Allergic disease" as used herein refers to any symptoms, tissue damage, or
loss of tissue function resulting from y.
[93] "Arthritic disease" as used herein refers to any disease that is characterized
by inflammatory lesions of the joints attributable to a variety of etiologies.
[94] "Dermatitis" as used herein refers to any of a large family of diseases of the
skin that are characterized by inflammation of the skin attributable to a variety of
etiologies.
[95] As previously bed, the term “dual PI3-kinase 5 / y selective inhibitor"
generally refers to a compound that ts the activity of the PI3—kinase 5 and y e
more ively than other isozymes of the PI3K family. The relative efficacies of
compounds as inhibitors of an enzyme activity (or other ical activity) can be
ished by determining the trations at which each compound inhibits the activity
18
WO 2014/195888 PCT/IB2014/061954
to a predefined extent and then ing the results. Typically, the preferred
determination is the concentration that inhibits 50% of the activity in a biochemical assay,
i.e., the 50% inhibitory concentration or "IC50". IC50 determinations can be accomplished
using conventional techniques known in the art. In general, an IC50 can be determined by
ing the activity of a given enzyme in the presence of a range of concentrations of
the inhibitor under study. The mentally obtained values of enzyme activity then are
plotted against the tor concentrations used. The concentration of the inhibitor that
shows 50% enzyme activity (as compared to the activity in the absence of any inhibitor) is
taken as the IC50 value. Analogously, other inhibitory concentrations can be defined
through appropriate determinations of ty. For example, in some settings it can be
desirable to establish a 90% inhibitory concentration, i.e., ICgo, etc.
[96] Accordingly, a dual PI3-kinase 6 / y ive inhibitor alternatively can be
tood to refer to a compound that exhibits a 50% inhibitory concentration (IC50) with
respect to PI3—kinase 5 and y, that is at least 10-fold lower, at least 20—fold lower, or at
least 30-fold lower than the IC50 value with respect to any or all of the other class I PI3K
family members. In an alternative embodiment of the invention, the term dual PI3—kinase 8
/ y selective inhibitor can be tood to refer to a compound that exhibits an IC50 with
respect to PI3—kinase 5 and y that is at least 30—fold lower, at least 50—fold lower, at least
lOO-fold lower, at least ZOO-fold lower, or at least 500-fold lower than the IC50 with
respect to any or all of the other PI3K class I family members. A dual PI3-kinase 5 / 7
selective inhibitor is typically administered in an amount such that it selectively inhibits
both PI3-kinase 8 and 7 activity, as bed above.
[97] In certain embodiments, the compounds of the present invention exhibit
PI3-kinase 5 and y inhibition almost equally (~ 1:1) or at a maximum ratio of 1:5, i.e., the
nd the of the present invention exhibit almost equal IC50 values for both P13—
kinase 5 and y enzyme or at most a 3 to 8 fold difference between the two.
,
[98] The methods of the ion may be applied to cell populations in vivo or
ex vivo. "In vivo" means within a living individual, as within an animal or human or in a
subject's body. In this context, the methods of the invention may be used eutically or
prophylactically in an individual. "Ex vivo" or “in vitro” means outside of a living
individual. Examples of ex vivo cell populations include in vitro cell cultures and
biological samples including but not limited to fluid or tissue samples obtained from
individuals. Such samples may be obtained by methods known in the art. Exemplary
biological fluid s include blood, cerebrospinal fluid, urine, and saliva. Exemplary
tissue samples include tumors and es f. In this context, the invention may be
19
WO 2014/195888 2014/061954
used for a variety of purposes, including therapeutic and experimental purposes. For
example, the ion may be used ex vivo or in vitro to ine the optimal schedule
and/or dosing of administration of a PI3—kinase 5 selective inhibitor for a given indication,
cell type, individual, and other parameters. Information gleaned from such use may be
used for experimental or diagnostic purposes or in the clinic to set protocols for in vivo
treatment. Other ex vivo uses for which the invention may be suited are described below or
will become apparent to those skilled in the art.
[99] The compounds of the present ion can be prepared by methods
known in the art, such as those described in International Publication Nos. WO
2011/055215, WO 51525, and WO 2013/164801, all of which are hereby
incorporated by reference.
Pharmaceutical Compositions
[100] The invention provides a pharmaceutical composition sing one or
more compounds of the present invention and one or more pharmaceutically acceptable
carriers or excipients. In one embodiment, the pharmaceutical composition includes a
therapeutically effective amount of a compound of the present invention. The
pharmaceutical composition may include one or more additional active ingredients as
described herein.
[101] The pharmaceutical carriers and/or excipients may be selected from
diluents, fillers, salts, disintegrants, binders, lubricants, glidants, wetting agents, controlled
release es, colorants, ngs, buffers, stabilizers, solubilizers, and combinations
thereof.
[102] In one embodiment, the pharmaceutical compositons bed herein
contain from about 0.1 mg to about 1,000 mg, such as from about 1 mg to about 1,000 mg
or from about 20 mg to about 800 mg or 50 mg to about 600 mg or 50 mg to about 600 mg
of one or more compounds of the present invention. 100 mg to about 400 mg of one or
more compounds of the present invention.
[103] The pharmaceutical compositions of the t invention can be
administered alone or in combination with one or more other active . Where
desired, the subject compounds and other agent(s) may be mixed into a preparation or both
components may be formulated into te preparations to use them in combination
separately or at the same time.
[104] The compounds and pharmaceutical compositions of the present invention
can be administered by any route that enables delivery of the compounds to the site of
20
WO 2014/195888 PCT/IB2014/061954
action, such as orally, asally, topically (e.g., transdermally), intraduodenally,
parenterally (including intravenously, intraarterially, intramuscularally, intravascularally,
intraperitoneally or by injection or infusion), intradermally, by intramammary,
intrathecally, intraocularly, retrobulbarly, intrapulmonary (e. g., aerosolized drugs) or
subcutaneously (including depot stration for long term release e.g., embedded-under
the-splenic capsule, brain, or in the cornea), sublingually, anally, rectally, vaginally, or by
surgical implantation (e.g., embedded under the splenic capsule, brain, or in the cornea).
[105] The itions can be administered in solid, olid, liquid or
gaseous form, or may be in dried powder, such as lyophilized form. The pharmaceutical
compositions can be packaged in forms ient for delivery, including, for example,
solid dosage forms such as es, sachets, cachets, gelatins, papers, tablets,
suppositories, pellets, pills, troches, and lozenges. The type of ing will generally
depend on the desired route of administration. Implantable sustained release formulations
are also contemplated, as are transdermal formulations.
Methods of Treatment
[106] The amount of the compound to be administered is dependent on the
mammal being treated, the severity of the disorder or condition, the rate of administration,
the disposition of the compound and the discretion of the ibing physician. However,
an ive dosage is in the range of about 0.001 to about 100 mg/kg body weight per day,
preferably about 1 to about 35 mg/kg/day, in single or divided doses. For a 70 kg human,
this would amount to about 0.05 to 7 g/day, ably about 0.05 to about 2.5 gfday An
effective amount of a compound of the invention may be administered in either single or
le doses (e. g., twice or three times a day).
[107] The compounds of the present invention may be used in combination with
one or more of anti-cancer agents (e. g., chemotherapeutic agents), therapeutic dies,
and radiation treatment.
[108] The compounds of the invention may be formulated or administered in
conjunction with other agents that act to relieve the symptoms of inflammatory conditions
such as encephalomyelitis, asthma, and the other diseases described herein. These agents
include non-steroidal anti-inflammatory drugs (NSAIDs).
EXAMPLES
[109] The examples and preparations ed below further illustrate and
exemplify the compounds of the present invention and methods of preparing such
compounds. It is to be understood that the scope of the present invention is not limited in
21
WO 2014/195888 PCT/IB2014/061954
any way by the scope of the following examples and preparations. In the following
examples molecules with a single chiral center, unless otherwise noted, exist as a racemic
mixture. Those molecules with two or more chiral s, unless otherwise noted, exist as
a racemic mixture of diastereomers. Single enantiomers/diastereomers may be obtained by
methods known to those skilled in the art.
[110] As used herein, superscript 1 refers to International Publication No. W0
11/055215 and superscript 2 refers to International Publication No. W0 12/151525. These
references describe how various intermediates are prepared.
Intermediates
Intermediate 1: 3-(3-flu0rophenyl)(1-hydr0xypropyl)-4H-chromenone: To a
solution of 2—(1-bromopropy1)(3-fluorophenyl)-4H-chromenone1 (8.80 g, 24.36
mmol ) in DMSO (85 ml), n—butanol (5 ml) was added and heated to 120° C for 3h. The
reaction mixture was cooled to room temperature (RT), quenched with water and extracted
with ethyl acetate. The organic layer was dried over sodium sulphate and concentrated
under d pressure. The crude product was purified by column chromatography with
ethyl acetate: petroleum ether to afford the title compound as a yellow solid (2.10 g, 29 %)
which was used without further purification in next step.
Intermediate 2: 3-(3-flu0r0phenyl)pr0pi0nyl-4H-chr0men0ne: DMSO (1.90 ml,
26.82 mmol) was added to dichloromethane (70 ml) and cooled to -78°C. Oxalyl chloride
(1.14 ml, 13.41 mmol) was then added. After 10 minutes, intermediate 1 (2.00 g, 6.70
mmol) in dichloromethane (20 ml) was added dropwise and stirred for 20 min.
ylamine (7 ml) was added and stirred for 1h. The reaction mixture was quenched
with water and extracted with dichloromethane. The organic layer was dried over sodium
sulphate and concentrated under reduced pressure. The crude t was purified by
column chromatography with ethyl acetate: eum ether to afford the title compound as
a yellow liquid (1.20 g, 60%) which was used as such in next step.
Intermediate 3: (+)/(—)—3-(3-flu0rophenyl)(1-hydroxypropyl)-4H-chr0men0ne :
To a on of intermediate 2 (0.600 g, 2.02 mmol) in DMF (7.65 ml) under nitrogen
purging, formic acid : lamine 5 : 2 azeotrope (1.80 ml) was added followed by
[(S,S)tethTstenRuCl] (3.0 mg). The reaction mixture was heated at 80°C for 1.5 hours
under continuous en g. The reaction mixture was quenched with water,
extected with ethyl acetate, dried over sodium sulphate and concentrated. The crude
t was purified by column chromatography with ethyl e: petroleum ether to
afford the title compound as a yellow solid (0.450 g, 74%). Mass: 299.0 (M+).
22
WO 2014/195888 PCT/IB2014/061954
Enantiomeric excess: 78%, enriched in the late eluting isomer (retention time: 9.72 min.)
as determined by HPLC on a chiralpak AD—H column.
Intermediate 4: (+)/(-)(3-flu0r0phenyl)(1-hydr0xypr0pyl)-4H-chr0men0ne :
The title nd was obtained as yellow solid (0.500 g, 83%) by using a procedure
similar to the one described for intermediate 3, using intermediate 2 (0.600 g, 2.02 mmol),
DMF (7.65 ml), formic acid : trietylamine 5 : 2 ope (1.80 ml) and
[(R,R)tethTstenRuCl] (3.0 mg). Mass: 298.9 (M+). Enantiomeric excess: 74.8%,
enriched in the fast eluting isomer (retention time: 8.52 min.) as determined by HPLC on a
chiralpak AD-H column.
Intermediate 5: (3-flu0r0phenyl)(1-hydr0xypr0pyl)-4H-chr0men0ne:
Step 1 : (R)(1-(benzyloxy)propyl)(3-fluorophenyl)-4H-chromenone: To 2-(3-
fluorophenyl)(2-hydroxyphenyl)ethanone (2.15 g, 9.36 mmol ), in dichloromethane ( 20
ml), HATU (4.27 g, 11.23 mmol), R-(+)2-benzyloxybutyric acid (2.00 g, 10.29 mmol)
were added and stirred for 10min, then triethylamine (14.0 ml, 101.1 mmol) was added
dropwise and stirred at RT for 24h. The reaction mixture was quenched with water,
extracted with romethane, dried over sodium sulphate and concentrated under
reduced pressure. The crude product was ed by column chromatography with ethyl
acetate: petroleum ether to afford the title compound as yellow solid (1.65 g, 45%). 1H-
NMR (8 ppm, CDC13, 400 MHz): 8.24 (dd, J = 79,15 Hz, 1H), 7.74 (dt, J = 7.1,1.7 Hz,
1H), 7.58 (dd, J: 8304 Hz, 1H), .06 (m, 10H), 4.51 (d, J: 7.8 Hz, 1H), 4.34 (d, J
= 7.8 Hz, 1H), 4.25 (dd, J = 7862 Hz, 1H), 2.17-1.90 (m, 2H), 0.95 (t, J = 7.5 Hz, 3H).
Mass: 389.0 (M+).
Step 2: (R)-3—(3-fluorophenyl)-2—(1-hydroxypropyl)-4H-chromen-4—one : To (R)-2—(l-
(benzyloxy)propyl)(3-fluorophenyl)-4H-chromenone (1.50 g, 3.86 mmol) in
dichloromethane (15 ml) cooled to 0°C and aluminium chloride (1.00 g, 7.72 mmol) was
added portion wise and stirred at RT for 6h. The reaction mixture was quenched with 2N
HCl on, ted with dichloromethane, dried over sodium sulphate and
concentrated under reduced pressure. The crude product was purified by column
chromatography with ethyl acetate: petroleum ether to afford the title compound as yellow
solid (0.552 g, 48%).‘1H-NMR (5 ppm, CDClg, 400 MHz): ' 8.24 (dd, J: 8.0,1.6 Hz, 1H),
7.72 (m, = 84,05 Hz, 1H), 7.44 (m, 2H), 7.12-7.01(m,3H), 4.49
, 1H), 7.52 (dd, J (t, J =
7.0 Hz, 1H), 1.94 (m, 2H), 0.93 (t, J = 7.5 Hz, 3H). Mass: (299.0(M+). Purity: 96.93%.
[a]25D —14.73 (c = 1, CHCl3). Enantiomeric : 85.92%, enriched in the fast eluting
isomer (retention time: 8.57 min.) as determined by HPLC on a chiralpak AS-3R column.
23
WO 2014/195888 PCT/IB2014/061954
Compound A
(RS)- 2-(1-(9H-purinylamino)propyl)(3-fluorophenyl)-4H-chromenone
To a solution of intermediate 1 (2.50 g, 8.41 mmol) in THF (25 ml), tert-butyl 9-trityl-9H-
6-ylcarbamate (4.81 g, 10.09 mmol) and triphenylphosphine (3.31 g, 12.62 mmol)
were added and stirred at RT for 5 min. ropylazodicarboxylate (2.5 ml, 12.62 mmol)
was added and stirred at RT for 2h. The reaction mixture was concentrated and column
chromatographed with ethyl acetate : petroleum ether to afford a yellow coloured
intermediate. To the intermediate, romethane (65 ml) and trifluoroacetic acid (7.9
ml) were added and the resulting mixture was stirred at RT for 12 h. The reaction mixture
was then basified with aqueous sodium bicarbonate solution, extracted with
dichloromethane and dried over sodium sulphate. The crude product was purified by
column chromatography with ol: dichloromethane to afford the title compound as
pale—brown solid (1.05 g, 30 %). MP: 148-150°C. Mass: 415.6 (M+).
Compound A1
(S)(1-(9H-purinylamino)propyl)(3-fluorophenyl)-4H-chromenone
Method A: To a solution of intermediate 3 (0.250 g, 0.838 mmol) in THF (5ml), tert—
butyl 9-trityl-9H-purin—6-ylcarbamate (0.479 g, 1.00 mmol) and triphenylphosphine (0.329
g, 1.25 mmol) were added and the resulting e was stirred at RT for 5 min.
Diisopropylazodicarboxylate (0.25 ml, 1.25 mmol) was then added and d at RT for 12
h. The reaction mixture was concentrated and column chromatographed with ethyl acetate:
pet.ether to afford the yellow coloured intermediate. To the intermediate in
dichloromethane (6 ml), roacetic acid (1.2 ml) was added d at RT for 12 h. The
reaction mixture was basified with aqueous sodium bicarbonate solution, extracted with
dichloromethane and dried over sodium sulphate. The crude product was purified by
column chromatography with ol: dichloromethane to afford the title compound as
an off-white solid (0.015 g, 4 %). MP: 137-140°C. 1H-NMR (5 ppm, DMSO'dfi, 400
MHz): 12.94 (s, 1H), 8.12-8.10 (m, 4H), 7.84-7.80 (m, 1H), 7.61 (d, J: 8.3 Hz, 1H), 7.50-
7.41 (m, 2H), 7.28-7.18 (m, 3H), 5.20-5.06 (m, 1H), 2.10-1.90 (m, 2H), 0.84 (t, J: 3.7 Hz,
3H). Enantiomeric excess: 77.4% as determined by HPLC on a chiralpak AD-H column,
enriched in the fast eluting isomer (retention time = 7.90 min).
24
WO 2014/195888 PCT/IB2014/061954
Method B : To a solution of intermediate 5 (2.60 g, 8.68 mmol) in THF (52 ml), tert—
butyl 9-trityl-9H-purinylcarbamate (4.96 g, 10.42 mmol) and triphenylphosphine (2.76
g, 13.03 mmol) were added and the resulting mixture was stirred at RT for 5 min.
Diisopropylazodicarboxylate (0.25 ml, 1.25 mmol) was then added and stirred at RT for 12
h. The reaction mixture was concentrated and column chromatographed with ethyl acetate:
petroleum ether to afford the yellow coloured intermediate. To the intermediate in
dichloromethane (55 ml), trifluoroacetic acid (14.2 ml) was added and stirred at RT for 12
h. The reaction mixture was basified with aqueous sodium bicarbonate on, extracted
with dichloromethane and dried over sodium sulphate. The crude product was purified by
column chromatography with methanol: dichloromethane to afford the title compound as
pale—yellow solid (1.00 g, 27 %). MP: 168—170°C. Mass: 416.5(M++1) Enantiomeric
: 86.5% as determined by HPLC on a pak AD-H column, enriched in the fast
eluting isomer (retention time = 7.90 min.).
Method C : The title compound was separated by preparative SFC conditions from
Compound A (1.090 g) on a CHIRALPAK AY-H column (250 x 30 mm; Sum) using
methanol : C02 (35:65) as the mobile phase at a flow rate of 80 g / min. Off-white solid
(0.378 g). e.e. 100%. Rt: 2.37 min. Mass: 416.1(M++1). MP: 149—152°C.
Compound A2
(R)(1-(9H-purinylamino)propyl)(3-fluorophenyl)-4H-chromenone
Method A: The title compound was obtained as an off-white solid (0.015 g, 4 %) by using
a procedure similar to the one bed for compound A1 (Method A) using utyl 9—
trityl-9H-purinylcarbamate (0.479 g, 1.00 mmol), intermediate 4 (0.250 g, 0.838 mmol),
triphenylphosphine (0.329 g, 1.25 mmol), THF (5 ml) and ropylazodicarboxylate
(0.25 ml, 1.25 mmol), followed by the cleavage of the intermediate with trifluoroacetic
acid (1.2 ml) and dichloromethane (6 ml). MP: 139-141°C. Mass: 415.6 (M+).
Enantiomeric excess: 81.6% as determined by HPLC on a chiralpak AD-H ,
enriched in the late eluting isomer (retention time = 10.81 min.)
Method B : The title compound was separated by preparative SFC conditions from
nd A (1.090 g) on a CHIRALPAK AY-H column (250 x 30 mm; Sum) using
methanol : C02 (35:65) as the mobile phase at a flow rate of 80 g / min. ite solid
(0.434 g). e.e. 98%. Rt: 3.71 min. Mass: 416.1(M++1). MP: 162—164°C.
25
WO 2014/195888 PCT/IB2014/061954
BIOLOGICAL ASSAYS
[111] The pharmacological properties of the compounds described herein may be
confirmed by a number of pharmacological assays. The cological assays which
have been carried out with the compounds according to the invention and/or their
pharmaceutically acceptable salts are exemplified below
Assay 1: Fluorescent Determination of P13 Kinase Enzyme Activity
[112] Phosphoinositide 3 kinases (PI3K) belong to a class of lipid kinases that
play a critical role in the regulation of several key cellular processes. The PI3K are e
of phosphorylating the oxy position of phosphoinositols thereby generating second
gers involved in downstream signalling events. The homogenous time resolved
fluorescence (HTRF) assay allows detection of 3,4,5—triphosphate (PIP3) formed as a
result of orylation of phosphotidylinositol 4,5-biphosphate (PIP2) by PI3K isoforms
such as a, [3, y or 8.
[113] PI3K m activity for 0t, [5, y or 5 was determined using a PI3K human
HTRFTM Assay Kit (Millipore, Billerica, MA) with modifications. All incubations were
carried out at room temperature. Briefly, 0.5 ul of 40X inhibitor (in 100% DMSO) or
100% DMSO were added to each well of a 384-well white plate (Greiner Bio-One,
Monroe, NC) ning 14.5 ul 1X on buffer /PIP2 (10 mM MgClz, 5 mM DTT,
1.38 uM PIP2) mix with or without enzyme, followed by 5 ul/well of 400 uM ATP and
incubated for an additional 30 minutes. Reaction was terminated by adding 5 ul/well stop
solution pore, Billerica, MA). 5 pl of detection mix (Millipore, Billerica, MA) were
then added to each well and was incubated for 6-18 hours in the dark. HRTF ratio was
measured on a microplate reader (BMG Labtech., y) at an excitation wavelength of
337 nm and emission wavelengths of 665 and 615 nm with an integration time of 400
msec counting delay of 50 msec. The results for Compounds A1 and A2 are shown in
Table 1 below. Comparative data for Compound A1 and Example 47 of WO 11/055215
are provided in Table 2.
TABLE 1
IC50 (nM)
Compound
----Pi3K5 Pi3K 0c Pi3K [5 Pi3K y
A1 >4000 24.05
A2 ND >10 uM
WO 95888 PCT/IB2014/061954
TABLE 2
PI3K 8 PI3K y
% Inhibition at 1 mm
Example 47 of 105.9 25.54 ND
Compound A1 23.85 _ 24.05
Assay 2: In Vitro Cell Proliferation Assay in Leukemic Cell Lines
[114] Growth inhibition assays were carried out using 10% FBS supplemented
media. Cells were seeded at a concentration of 5000 — 20,000 cells/well in a 96-well plate.
Test compounds at a tration range from 0.01 to 10000 nM were added after 24 h.
Growth was assessed using the 3-[4,5-dimethylthiazolyl]-2,5-diphenyltetrazolium
bromide (MTT) dye reduction test at 0 h (prior to the addition of the test compound) and
72 h after the addition of test compound. Absorbance was read on a Fluostar Optima
(BMG Labtech, y) at a wave length of 450 nm. Data were analysed using
GraphPad Prism and percent tion due to the test nd compared to the control
was calculated accordingly.
[115] Compound A1 caused a reduction in T-lymphoma (MOLT-4, Jurkat,
CCRF—CEM, Hut-78 & HuT-102) cell ity with G150 values ranging from 1—5 uM for
the dose range tested. Additionally, the compound did not display any apparent
cytotoxicity over the 72-h incubation period up to 10 uM.
Assay 3: Inhibition of AKT phosphorylation in leukemic cell lines
[116] MOLT-4, , CCRF—CEM, Hut-78, HUT-102, $624 and HH cells were
incubated with desired concentrations of compound for 48 h. Cells were lysed and pAKT
determined by Western Blotting. Bands were quantified using ImageJ and normalized to
actin.
[117] Compound A1 caused a reduction in pAKT expression in T-lymphoma
4, Jurkat, CCRF—CEM, Hut-78 & HuT—102) cell lines with EC50 values ranging
from 0.5-2 [1M for the dose range tested. The results are shown in Figure 8.
Assay 4: Inhibition of PI3K 6 and y signalling in basophils from Human Whole Blood
27
WO 95888 PCT/IB2014/061954
[118] PI3K 5 and y signalling in basophils manifested by an tion of anti—
FcaRl or fMLP induced CD63 expression is a useful pharmacodynamic marker
determined using the AST® kit (Buhlmann Laboratories, Switzerland). Briefly, it
involves the following steps:
0 Mix the anti-coagulated blood sample by inverting the venipuncture tube
several times;
0 Prepare fresh and pyrogen—free 3.5 ml polypropylene or polystyrene tubes
suitable for Flow Cytometry measurements;
0 Add 49 ul of patient’s whole blood to each tube;
0 Add 1 ul of 10% DMSO (background) or compound (10% DMSO) to the
assigned tubes and mix gently. Incubate at room temperature for 15 minutes;
0 Pipet 50 ul of the ation buffer (background) or anti- FcaRI Ab or or
fMLP to each tube;
0 Add 100 pl of Stimulation Buffer to each tube;
0 Mix gently. Add 20 ul Staining Reagent (1:1 mix of FITC-CD63 and PE—
CCR3) to each tube;
0 Mix gently, cover the tubes and incubate for 15 minutes at 37°C in a water
bath. (using an incubator will take about 10 minutes longer incubation time due
to less efficient heat transfer);
0 Add 2 ml pre—warmed (18-280C) Lysing Reagent to each tube, mix gently;
0 Incubate for 5 -10 minutes at 18-280C;
0 Centrifuge the tubes for 5 minutes at 500 x g;
0 Decant the supernatant by using blotting paper;
0 Resuspend the cell pellet with 300—800 ul of Wash ; and
0 Vortex gently and acquire the data on the flow cytometer within the same day.
[119] Percent CD63 positive cells within the gated il tion were
determined in different treatment groups and normalized to e control.
[120] Compound A1 exhibited a EC50 of < 40 nM for chR1(PI3K 5) and a IC50
of < 40 nM for fMLP ( PI3K y) ( n=10). The results are shown in Figure 9.
Assay 4A: Cellular Activity Demonstrating ivity of Compound A1 towards
PI3K Delta and PI3K Gamma Isoform
Assay 4A1: Anti-IgM induced B-Cell Proliferation (for PI3K6 selectivity)
28
WO 2014/195888 PCT/IB2014/061954
[121] The ive of this study was to assess the inhibitory potential of
Compound Al on gM induced human B-cell proliferation.
Plating and treatment
Isolated B-cells were re-suspended to 1.0 X 106 cells per ml. 100 ul of cell
suspension was added to each well of a 96-well plate. Triplicates were ined.
50 ul of drug dilution was added and mixed well. A DMSO blank and inducer
blank were maintained.
Treated plate was incubated for 30 min at 37°C, 5% C02 and then 50 ul of 4X
inducer was added and mixed by ing.
Plate was ted at 37°C, 5% C02 for 72 h.
Media was aspirated and 150 pl of DMSO was added to dissolve the formazan
crystals.
Absorbance was read at A560 and A640 nm.
[122] The data demonstrates the inhibitory potential of Compound Al on PI3K8
mediated induction of human B-cell proliferation. See, e.g., Backer er al. Journal of
Immunology, 134: 3532-3538, 1985.
Assay 4A2: LPA induced AktS473 Phosphorylation in 3T3 Fibroblasts (for PI3KB
Selectivity)
[123] The objective of this study was to determine the effect of Compound Al on
PI3KB kinase mediated LPA induced AktS473 phosphorylation in 3T3 fibroblasts.
3T3 cells were treated with desired concentrations of the test compound for 15
min. 1 ml of 2X LPA was added such that the final concentration was 5 uM
and incubated for 5 min.
Media was discarded and washed with 1 ml of ld 1X PBS.
250 pl of cell lysis buffer was added and incubated on ice for 30 min.
Samples were centrifuged and supernatant was at —80°C until is.
Samples were analyzed by Western Blotting using pAKT (S473) as the primary and
anti-rabbit IgG-HRP as a secondary antibody.
Intensity of the bands was determined using ImageJ 1.42q (NIH, USA) and
normalized to Actin (loading control). Data was d using GraphPad Prism
(Version 5.02).
29
WO 2014/195888 PCT/IB2014/061954
[124] The results demonstrate the selectivity of nd A1 over the beta
isoform of PI3K. See erque et al., J. Biol. Chem. 278, 39830-39838, 2003.
Assay 4A3: c5a Induced AktS473 Phosphorylation in RAW 264.7 Macrophages (for
PI3K7 Selectivity)
[125] The objective of this study was to determine the effect of Compound Al on
PI3Ky kinase mediated c5a induced AktS473 phosphorylation in RAW 264.7
macrophages.
0 RAW 264.7 cells were treated with desired concentrations of the test
nd for 15 min. 1 ml of 2X c5a was added such that the final
concentration was 50 ng/ml and incubated for 15 min.
0 Media was ded and washed with 1 ml of ice—cold 1X PBS.
0 250 pl of cell lysis buffer was added and incubated on ice for 30 min.
0 Samples were centrifuged and supernatant was stored at -80°C until analysis
0 Samples were analyzed by Western Blotting using pAKT (S473) as the primary
and abbit IgG-HRP as a secondary antibody.
0 ity of the bands was determined using ImageJ 1.42q (NIH, USA) and
normalized to Actin (loading control). Data was plotted using GraphPad Prism
on 5.02).
[126] Inhibition of pAktS473, a downstream marker of PI3K8 signaling suggests
a role for Compound Al in the oncogenic pathways regulated by Akt in c5a induced RAW
264.7 cells. See To et al. Am. J. Respir. Crit. Care Med, 182, 897-904, 2010.
Assay 4A4: PDGF Induced Akt Phosphorylation in 3T3 cells (for PI3K a Selectivity)
[127] The objective of this study was to determine the effect of Compound Al on
PI3KOL kinase mediated AktS473 phosphorylation in PDGF induced 3T3 fibroblasts.
0 3T3 cells were treated with desired trations of the test compound for 15
min. 1 ml of 2X PDGF was added such that the final concentration was 20
ng/ml and incubated for 10 min.
0 Media was discarded and washed with 1 ml of ice-cold 1X PBS.
0 250 pl of cell lysis buffer was added and incubated on ice for 30 min.
0 Samples were centrifuged and supernatant was collected and stored at -80°C
until analysis.
30
WO 95888 PCT/IB2014/061954
0 Samples were ed by Western Blotting using pAKT (S473) as the primary
and anti-rabbit IgG-HRP as a secondary antibody.
0 Intensity of the bands was determined using Image] 1.42q (NIH, USA) and
normalized to Actin (loading control). Data was plotted using GraphPad Prism
(Version 5.02).
[128] No inhibition was observed at 10 uM of Compound Al, demonstrating the
selectivity of Compound A1 over the alpha isoform of PI3K. See Albuquerque er al., J.
Biol. Chem. 278, 39830-39838, 2003.
[129] The Table below summarizes the results from Assyas 4.
CELLULAR ACTIVITY DEMONSTRATING SELECTIVITY OF COMPOUND Al
TOWARDS PI3K DELTA AND PI3K GAMMA M
Cellular IC50 PI3K alpha (PDGF induced pAKT in 3T3 fibroblasts) >10000 nM
Cellular IC50 PI3K beta (LPA induced pAKT in 3T3 lasts) 2067 nM
Cellular IC50 PI3K delta (anti-IgM induced human B-cell proliferation 38.1 nM
Cellular IC50 PI3K gamma (05a induced pAKT in RAW macrophages) 223 nM
Assay 5: tion of Apoptosis in Leukemic Cell Lines
[130] Apoptosis in leukemic cells was determined using an in-situ Caspase 3 kit
(Millipore, US) as outlined below:
0
Seed leukemic cells - at a density of 1X106 cells/well in a 6 well plate
0 Add test compound/DMSO at desired concentrations
0 Incubate the plate for 24 hrs at 37°C in 5% C02 incubator
0 Collect cells in a 2ml fuge tube
0 Add 1.6 uL of y prepared 5X FLICA reagent and mix cells by slightly
flicking the tubes
0 Incubate tubes for 1 hour at 37°C under 5% C02
0 Add 2 ml of lX wash buffer to each tube and mix
0 Centrifuge cells at <400 x g for 5 minutes at room temperature.
0 Carefully remove and discard supernatant, and gently vortex cell pellet to disrupt
any cell-to-cell clumping.
0 Resuspend cell pellet in 300ul of lX wash buffer
0 Place 100 uL of each cell suspension into each of two wells of a black microtiter
plate. Avoid creation of bubbles.
0 Read ance of each microwell using an excitation wavelength of 490 nm and
an emission wavelength of 520 nm
31
WO 2014/195888 PCT/IB2014/061954
0 Percent increase in caspase-3 activity manifested by an increase in cence
compared to the control blank is to be calculated.
[131] Compound Al caused a dose-dependent induction in caspase-3 activity in
T-lymphoma (MOLT-4, Jurkat, CCRF-CEM, Hut-78 & HuT-102) cell lines.
Assay 6: Screening for pAKT Inhibition in Human Primary CTCL Cells
[132] Flow cytometry analysis of pAKT inhibition: Purified malignant T cells
were isolated from donors and cultured overnight in RPMI/1% BSA. Cells were incubated
with the test nd for 1.5 hr with a cytokine mix added for the final 30 minutes. The
composition of the cytokine mix was 20 ng/ml 1L2 + 5 ng/ml 1L7 + 10 ng/ml IL15 + 10%
FBS. AKT phosphorylation was determined by flow cytometry.
[133] Treatment with Compound A1 caused a dose dependent reduction AKT
orylation with EC50 ranging from 40-300 nM (% inhibition data).
Assay 6A: Screening for Anti-Cancer Activity in Human CLL Cells
[134] Primary CLL cells were enriched using Rosette-Sep B cells from Stem Cell
Technology, generally giving purity of > 97% of B cells/CLL cells. Cells were seeded at
2.5 x 105 per well in a 96 well with either serum free medium (SFM) or SFM + 10% heat-
inactivated fetal bovine serum (volume 100 microliters) in the presence of desired
concentrations of the test compound and ed for 3 days at 370 C in a carbon dioxide
incubator. Cytotoxicity was determined using the MTS assay.
[135] Compound A1 induces cytotoxicity in CLL cells with a median ECSO of <
100 nM in serum-free and < 700 nM in 10% FBS media.
Assay 6B: Screening for Anticancer Activity in Patient Derived B-Lymphoma Cells
[136] Primary cells from lymphoid tumors were exposed to the test compound
[Compound Al] to assess the induction of cell death. Cells were derived from diffuse large
B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), splenic al zone
lymphoma (SMZL), extranodal al zone ma (EMZL), or chronic lymphocytic
leukemia (CLL, no.=l). Cells were d with desired concentrations of the compound
and apoptosis (Annexin V/PI) was ed by flow-cytometry after a 48-h incubation
.
[137] Almost all the primary cells d from B-cell lymphomas underwent an
increase in cell death when exposed to the test compound (Compound A1) at a
32
WO 2014/195888 PCT/IB2014/061954
concentration of 4 uM. The phenomenon appeared more evident among primary cells
derived from small cell lymphomas (MZL, MCL, and CLL).
Assay 6C: Inhibition of AKT orylation in B-Lymphoma Cell Lines
[138] LY-l, LY-10, Daudi, JEKO, REC and MAVER cells were incubated with
desired concentrations of [compound Al] for 48 hours. Cells were lysed and pAKT was
determined by Western Blotting. Bands were quantified using ImageJ and normalized to
actin.
[139] Compound A1 exhibited an EC50 of 20 — 200 nM across the B-lymphoma
cell lines tested.
Assay 6D: Cytokine Assay in Anti-Human CD3 and CD28 Vo-Stimulated Primary T-
Cells
[140] The ive of this study was to assess the inhibitory potential of
Compound Al on cytokines produced by anti-human CD3/CD28 co-stimulated primary T-
cells.
Plating and Treatment
0 Plates were coated with 50 ul of anti-human CD3 at a concentration of 100 ng/ml
either overnight at 4°C or for 2 h at 37°C. After incubation, plates were washed
twice with sterile PBS to remove unbound antibody.
0 Isolated human T-cells were re—suspended to 0.625 x 106 cells per ml in 1.5ml
tubes and 1 ul of drug dilution ) was added. A DMSO blank and un-
induced blank were maintained.
0 Cells were incubated with compound at room temperature for 30 min and then
added to uman CD3 coated wells of a 96-well plate, 240 pl each. Anti-
human CD28 was added immediately, 10 ul (25X) per well.
0 Plate was incubated at 37°C, 5% C02 for 24 h.
0 Plates were centrifuged at 4000 rpm at room temperature, supernatant was
collected and stored at —20°C.
0 Cytokines were determined using a commercial ELISA kit with absorbance read
at 450 and 570 nm.
[141] IC50 values were ated from eight independent ments.
Compound A1 inhibited anti-human 28 induced T cell cytokines with an IC50 of
33
WO 2014/195888 PCT/IB2014/061954
24, 9.54 and 20.6 nM for TNFOL, IFNy and IL2 respectively. The results are shown in
Figure 10.
Assay 7: lysaccharide Induced ary Neutrophilia in Female Wistar Rat
Model
[142] An exaggerated recruitment and subsequent activation of neutrophil is
likely to be important for the development and course of several inflammatory diseases in
the airways and lungs, such as severe asthma, chronic ctive pulmonary e,
cystic fibrosis, and acute atory distress syndrome. The mechanisms by which
neutrophil bute to these diseases may e the release of proteolytic enzymes,
such as phil elastase, and free oxygen radicals. When released, these compounds can
cause bronchoconstriction, bronchial hyperreactivity, hyper-secretion, epithelial damage,
and tissue remodelling in the airways.
[143] After the quarantine period, fasted animals were randomized and divided
into various groups depending on their body s. The test compound [Compound Al]
was prepared as a suspension in a e consisting of 0.5% methylcellulose in which
Tween 80 as a suspending agent. The compound or vehicle was administered by oral
gavage in a volume of lOmL/kg. Female Wistar rats were anaesthetized with ketamine
and LPS solution was administered intratracheally one hour after compound administration
at a dose of 1 mg/kg. 6 h after LPS instillation, animals were exsanguinated under
hesia, and then a was cannulated and the lungs were lavaged with 5-ml
aliquots of heparinised PBS (1 unit/ml) four times through tracheal cannula (total volume
20 ml). Bronchoalveolar lavage (BAL) fluid was been stored at 2-8 C’C until assayed for
total cell and differential leukocyte count. Bronchioalveolar fluid was centrifuged (500xg
for 10 min) and the resulting cell pellet was resuspended in 0.5 ml of heparinised saline.
The total numbers of white blood cells were determined in BAL fluid or blood by using a
blood cell counter and was adjusted to 1x106 cell/ml. Differential cell count was calculated
ly. One hundred microliters of the cell suspension was centrifuged using cytospin 3
to prepare a cell smear. The cell smear was stained with a blood staining solution for
differentiation and slides were microscopically observed to identify eosinophil according
to their morphological characteristics. The number of each cell type among 300 white
blood cells in the cell smear was determined and expressed as a percentage. The number of
eosinophil in each BALf or blood was calculated.
[144] Compound Al showed a dose-dependent reduction of neutrophil infiltration
into the lungs with an ED50 of 6.5 mg/kg suggesting a therapeutic role in inflammatory
disorders. The results are shown in Figure l.
34
WO 2014/195888 PCT/IB2014/061954
Assay 8: Lipopolysaccharide-Induced Rat Air Pouch Model of Inflammation
[145] Leukocyte recruitment and the formation of pro—inflammatory mediators,
including different cytokines, are the hallmark of an atory response. The air-pouch
model was originally ped as a facsimile um for the study of inflammatory
processes that occur in rheumatoid arthritis (RA). The model allows the differential
quantification of leukocyte species that accumulate in the air-pouch wall (tissue) as well as
those that transmigrate into the air-pouch cavity (lavage), and it allows the characterization
of the chemokines and adhesion molecules responsible for diapedesis induced by a variety
of inflammatory stimuli.
[146] Female Wistar rats (175—200 g) were acclimatized for seven days prior to
the start of the experiment. Animals were randomly distributed to various groups based on
their body weights. Animals were anaesthetised with ether and subcutaneous air pouches
were made by injecting 20 ml of sterile air under the skin in the scapular area (day 0)
and maintained with a second lO-ml ion of sterile—filtered air on day 4. On day 6, oral
treatment was commenced l h prior to induction of inflammation by so. injection of LPS
solution on day 6. A volume of 5-m1 of LPS solution dissolved in sterile saline (lOOug/kg)
was injected into each pouch. Samples of pouch fluid were taken at 6 h after
administration of LPS by flushing the pouch with 5 ml of sterile saline and withdrawing 4
ml of fluid. The numbers of ytes present in pouch fluid was determined
microscopically using a haemocytometer. Differential cell content was determined by
microscopic examination of fluid smears stained with Diff-Quik.
[147] Compound A1 caused a dose-dependent reduction of neutrophil migration
into the rat air pouch with an ED50 of 2.6 mg/kg ting a therapeutic role in
rheumatoid arthritis. The results are shown in Figure 2.
Assay 9: Lipopolysaccharide Induced TNF-oc Production
[148] Fasted female Wistar rats were randomized into different groups ing
on their body weights. Test compound (Compound Al) was prepared as a suspension in a
vehicle ting of 0.5% methylcellulose. The compound or vehicle was administered by
oral gavage in a volume of lOmL/kg. LPS solution was administered intraperitoneally one
hour after nd stration at a dose of 0.3 mg/kg. Blood was collected in serum
separator tubes Via cardiac re ninety minutes after LPS ion. Serum was
separated and stored at —20 CC and will be analysed for TNFa by ELISA.
35
WO 2014/195888 PCT/IB2014/061954
[149] Compound A1 reduced plasma TNFa concentrations suggesting a
therapeutic role in inflammatory disorders (percent inhibition observed at 1, 3 and 10
mg/kg was 5%, 15%, and 40%, respectively). The results are shown in Figure 3.
Assay 10A: min Induced Pulmonary Eosinophilia in Male Guinea Pigs
[150] Airway inflammation and hyper-responsiveness (AHR) are hallmarks and
distinguishing features of bronchial asthma. Provocation of pre-sensitized mice with the
same allergen induces airway inflammation with preferential philic infiltration and,
as a consequence, AHR. Pulmonary eosinophilia and airway lling in conjunction
with altered neural l of airway tone and airway epithelial mation may
contribute to AHR in asthma.
[151] After the quarantine period, 0.3 mL of blood samples was collected from
orbital vein by retro-orbital plexus method from each individual animal and ed on a
cell analyser (ADVIA 2120, Siemens). Based on their total cell count, guinea pigs were
randomized and divided into various groups. Ear pinna was marked with an indelible
marking pen for identification. On day 0, weights were recorded and animals were
sensitized with 50ug of min (OVA) and 10 mg of alum solution (1 mL)
intraperitoneally. On day 7 and day 14, the above sensitization protocol was repeated.
Animals were ed for any signs of illness or reaction to the sensitization up to day 19
and recorded if any. On day 19, 20, and 21, after the treatment with test compound by oral
gavage, 30 mins later animals were exposed to 0.5 % w/v, 0.5% and 1% Ovalbumin
challenge respectively. Control & sham group animals were treated with 0.5% w/v methyl
ose (vehicle). Sham control groups were sensitized with 10 mg of alum on day 0, 7 &
14 and exposed to saline solution (SAL) with the same nebulization rate on day 19. 20 and
21. Twenty hours after last OVA challenge, airway hyperresponsiveness was measured by
whole body plethysmograph against cumulative doses of methacholine challenge (75, 100,
125 & 150 ug/ml), after measuring the airway response, blood samples and BAL fluid was
collected. Samples were analysed for total cell count by using neubuear r under
microscope and differential leukocyte count was done manually.
[152] As depicted in the Figures 4A and 4B, nd A1 caused a icant
dose dependent reduction in airway hyperresponsiveness against methacholine challenge
of sensitized Guinea pigs.
[153] As depicted in the Figures 4C-4E, Compound A1 caused a icant dose
dependent reduction in eosinophil infiltration into the bronchoalveolar lavage fluid of
sensitized Guinea pigs.
36
WO 2014/195888 PCT/IB2014/061954
Assay 10B: Murine Asthma Model
[154] Airway inflammation and hyper—responsiveness (AHR) are hallmarks and
distinguishing features of bronchial asthma. Provocation of pre-sensitized mice with the
same allergen induces airway inflammation with preferential philic infiltration and,
as a consequence, AHR. Pulmonary eosinophilia and airway remodelling in conjunction
with altered neural control of airway tone and airway lial desquamation may
contribute to AHR in asthma. After the quarantine period, based on their body weights,
mice were randomized and divided into four groups (n=7). Tails were marked with an
indelible g pen for identification. On day 0, s were recorded and animals
were sensitized with IOOug of Ovalbumin and 10 mg of alum solution (0.2 mL)
intraperitoneally. On day 7 and day 14, the above sensitization protocol was repeated.
s were observed for any signs of illness or reaction to the sensitization up to day 24
and recorded if any. On day 24, 25, and 26, after the ent with test compound by oral
gavage, 30 mins later animals were exposed to 10 % w/v min challengeControl
and sham group animals were treated with 0.5% w/v methyl ose (vehicle). Sham
control groups were sensitized with 10 mg of alum on day 0, 7 & l4 and exposed to saline
solution with the same nebulization rate on day 24, 25 & 26. Forty eight hours after last
OVA challenge, airway hyperresponsiveness was measured by whole body
plethysmograph against cumulative doses of methacholine challenge (2.5, 10, 50 and 100
mg/ml), after measuring the airway response, blood samples and BAL fluid was collected.
Samples were analysed for total cell count by using neubuear chamber under microscope
and differential leukocyte count was done manually.As depicted in the Figures 5A and 5B,
Compound A1 at a dose of 3 mg/kg caused a significant reduction in airway
hyperresponsiveness against holine nge of ovalbumin sensitized mice.
[159] As depicted in the Figures 5C-5E, Compound A1 at a dose of 3 mg/kg
caused a significant inhibition of eosinophil infiltration into the oalveolar lavage
fluid of ovalbumin sensitized mice.
Assay 11: Collagen Induced Arthritis in Lewis Rats
[160] Female wistar rats were acclimatized for seven days prior to the start of the
ment and were randomly distributed to various groups based on their body weights.
On day 0, s were treated by intradermal injection of 500 pg of bovine collagen type
II emulsified with complete Freund’s adjuvant (IFA) containing MTB (4 mg/mL)
delivered at the base of the tail. On day 7 after primary immunization, animals were treated
37
WO 2014/195888 2014/061954
by r injection of 300 ug C11 in incomplete Freund's adjuvant by intradermal
injection at the base of the tail. Onset of arthritis in ankle joints usually became visually
apparent between days 12 and 14. Animals were treated with test compound or vehicle
(orally administered) from the day after onset of arthritis until end of the experiment (day
28) as a therapeutic group. Arthritis Scores were taken by visually examination for signs of
joint inflammation regularly throughout the study period. Body weights and paw volumes,
paw thickness has been taken on day 0, 3, 7, 10, 12, 14, 17 21, 24 and 28. On d28, at the
end of the study, blood has been withdrawn at sy and processed to serum or plasma
and all joints were taken and both fore paw and hind paws were fixed in 10% formalin for
histopathology analysis after taking the small piece of tissue from each joint and stored at —
80°C for cytokine analysis in tissue homogenate. Clinical Scoring Criteria for Fore and
Hind Paws: 0 = normal; 1 = one hind or fore paw joint affected or minimal diffuse
erythema and ng; 2 = two hind or fore paw joints affected or mild diffuse erythema
and ng; 3 = three hind or fore paw joints affected or moderate diffuse erythema and
swelling; 4 = marked diffuse erythema and swelling, or = four digit joints affected; 5 =
severe diffuse erythema and severe swelling entire paw, unable to flex digits.
[161] Compound Al dosed therapeutically in the rat CIA model demonstrates
significant efficacy in reduction of knee and as well as ankle swelling.
[162] ogical analysis of joints at study end demonstrates complete structural
preservation at 15 mg/kg Compound Al. For comparison, a vehicle-dosed animal shows
synovial (S) inflammation and significant ce of bone resorption, pannus formation,
and cartilage degradation and, as ed in Figures 6A-6D, Compound Al shows
significant reduction in individual and summed histopathological scores for both knee and
ankle.
Assay 12: Acute CSE Induced Cell ation in Male Balb/c Mice
[163] Animals (male Balb/c mice) are to be acclimatized for seven days prior to
the start of the experiment. Animals are to be randomly distributed to various groups based
on their body weights. On day 1, mice are to be administered the test compound or e
by oral/intranasal route and after 1 hr the test compound stration the animals are to
be anaesthetised with ether and cigarette smoke extract is to be administered by asal
route in volume of SOul/mouse and repeated the CSE exposure to animals daily after the
test compound administration for four days (dl to d4). On day 5, 24 hours after last CSE
exposure animals are to be exsanguinated under anesthesia, and the trachea is to be
cannulated and the lungs are lavaged with 0.5-ml aliquots of heparinised PBS (1 unit/ml)
38
WO 2014/195888 PCT/IB2014/061954
four times through tracheal cannula (total volume 2 m1). BAL stored at 2-8 0C until
assayed for total cell and differential leukocyte count. Bronchioalveolar fluid is to be
centrifuged (500xg for 10 min) and the resulting cell pellet has to be resuspended in 0.5 ml
of heparinised saline. The total number of white blood cells is to be determined in BAL
fluid and blood using a blood cell counter and adjusted to 1x106 cell/ml. Differential cell
count is to be calculated manually. Forty microliters of the cell sion is to be
centrifuged using cytospin 3 to prepare a cell smear. The cell smear is to be d with a
blood staining solution for differentiation and microscopically has to be observed to
fy eosinophil according to their morphological characteristics. The number of each
cell type among 300 white blood cells in the cell smear are to be determined and to be
sed as a percentage, and the number of neutrophils and macrophages in each BALf
are to be calculated.
Assay 13: Sub-chronic CSE d Cell Infiltration in Male Balb/c Mice
[164] Animals (male Balb/c mice) are to be acclimatized for seven days prior to
the start of the experiment. Animals are to be randomly distributed to various groups based
on their body weights. On day 1, animals are to be anaesthetised with ether and cigarette
smoke extract is to be stered by intranasal route in volume of SOul/mouse and
repeated the CSE exposure to animals daily for eight days (dl to d8). On day 9, mice are to
be administered by test compound or vehicle by oral/intranasal route and after 1 hr test
compound administration animals are to be anaesthetised with ether and cigarette smoke
extract is to be administered by asal route in volume of 50ul/mouse and animals are
to be d to CSE daily after the test compound administration for next three days (d9
to d1 1), on day 12, twenty four hours after last CSE re animals are to be
exsanguinated under anesthesia, and the trachea is to be ated and the lungs are to be
lavaged with 0.5-ml aliquots of heparinised PBS (1 unit/n11) four times h tracheal
cannula (total volume 2 ml). BAL stored at 2-8 °C until assayed for total cell and
differential leukocyte count. Bronchioalveolar fluid was centrifuged (SOOXg for 10 min)
and the resulting cell pellet is to be resuspended in 0.5 ml of heparinised saline. The total
numbers of white blood cells are to be determined in BAL fluid and blood using a blood
cell counter and adjusted to l><106 cell/ml. Differential cell count was calculated ly.
Forty microliters of the cell suspension is to be centrifuged using cytospin 3 to prepare a
cell smear. The cell smear is to be stained with a blood staining solution for differentiation
and microscopically observed to identify eosinophil according to their morphological
characteristics. The number of each cell type among 300 white blood cells in the cell
39
WO 2014/195888 2014/061954
smear has to be determined and expressed as a percentage, and the number of neutrophils
and macrophages in each BALf are to be calculated.
Assay 14: Reversal of Corticosteroid Insentivity in Cigarette Smoke Extract Induced
Pulmonary Inflammation (COPD) Model
[165] Female Balb/c mice are to be acclimatized for seven days prior to the start
of the experiment. Animals are then to be randomly distributed to various groups based on
their body weights. On day 1, s are to be anaesthetised with ether and cigarette
smoke extract is to be administered by intranasal route in volume of SOul/mouse and
animals are to be exposed to CSE daily for next five days (dl to d6). On day 7, mice are to
be administered by dexamethasone at 10 mg/kg by oral gavage and 60 mins later, mice are
to be stered with CSE by asal route and it has to be repeated for next four days
(d7 to dll). From day 9 to dayll, s are to be administered by test compound or
vehicle by oral/intranasal route and 30 mins after dexamethasone administration and 30
mins later animals are to be anaesthetised with ether and cigarette smoke extract is to be
administered by intranasal route in volume of 50ul/mouse and animals are to be exposed to
CSE daily after the test compound administration for next two days (i.e. d9 to dll), on
d12, twenty four hours after last CSE exposure animals are to be exsanguinated under
anesthesia, and the trachea is to be cannulated and the lungs are to be lavaged with 0.5-ml
ts of heparinised PBS (1 unit/n11) four times through tracheal cannula (total volume 2
ml). BAL has to be stored at 2-8 0C until assayed for total cell and differential leukocyte
count. Bronchioalveolar fluid is to be centrifuged (SOOXg for 10 min) and the ing cell
pellet has to be resuspended in 0.5 ml of heparinised saline. The total number of white
blood cells is to be determined in BAL fluid and blood using a blood cell counter and
adjusted to 1x106 cell/ml. Differential cell count is to be calculated manually. Forty
microliters of the cell suspension is to be centrifuged using cytospin 3 to prepare a cell
smear. The cell smear is to be stained with a blood staining solution for differentiation and
microscopically has to be observed to identify eosinophil according to their morphological
characteristics. The number of each cell type among 300 white blood cells in the cell
smear are to be determined and will be expressed as a percentage, and the number of
phils and macrophages in each BAL fluid are to be calculated.
Assay 15: Acute Cigarette Smoke Induced Cell Infiltration in Male Balb/c Mice
[166] Animals (male Balb/c mice) are to be atized for seven days prior to
the start of the experiment. Animals are then to be randomly buted to various groups
40
WO 2014/195888 PCT/IB2014/061954
based on their body s. On day 1, mice is to be administered test compound or
vehicle by oral/intranasal route and after 1 hr test compound administration animals are to
be placed in whole body exposure box. On day 1 and d2 mice are d to the
mainstream smoke of 6 cigarettes and of 8 ttes on day 3, and of 10 cigarettes on day
4. Exposure to the smoke of each cigarette lasts for 10 min (cigarette are to be completely
burned in the first two minutes and followed by an air flow with animal ventilator and
next 20 min exposure with fresh room air. After every second cigarette an onal break
of 20 min with exposure to fresh room air is to be conducted. Control animals are to be
exposed to room air chamber. From day 1 to d4 animals are administered by test
compound either oral or intranasal route. On day 5, 24 hours after last cigarate smoke (CS)
exposure animals are exsanguinated under anesthesia, and the trachea is to be cannulated
and the lungs are d with 0.5-ml aliquots of heparinised PBS (1 unit/n11) four times
through tracheal cannula (total volume 2 ml). Bronchioalveolar (BAL) collected is to be
stored at 2-8 C’C until assayed for total cell and differential leukocyte count. BAL fluid is to
be centrifuged (SOOXg for 10 min) and the resulting cell pellet is resuspended in 0.5 ml of
heparinised saline. The total number of white blood cells is to be ined in BAL fluid
and blood using a blood cell counter and adjusted to 1x106 cell/ml. Differential cell count
is calculated manually. Forty microliters of the cell suspension is centrifuged using
cytospin 3 to prepare a cell smear. The cell smear is stained with a blood staining solution
for differentiation and microscopically observed to identify eosinophil according to their
morphological characteristics. The number of each cell type among 300 white blood cells
in the cell smear are to be ined and expressed as a percentage, and the number of
phils and macrophages in each BAL fluid are to be ated.
Results: As depicted in s 7A and 7B, Compound Al reduced macrophages and
neutrophil infiltration into BALF thereby indicating a therapeutic role in chronic
ctive ary diseases
Assay 16: Ovalbumin-Induced Nasal phil and Neutrophil Accumulation in
Mice
[167] Animals (mice) are to be acclimatized for seven days prior to the start of the
experiment. Animals are then to be randomly distributed to various groups based on their
body weights. Animals are to be immunized with OVA (40 ug/kg i.p.) on day 1 and 5. In
order to elicit local inflammatory responses in the nose, mice are to be repeatedly
challenged intra-nasally (IOuL/per nostril) on days 12-19 with OVA (3% OVA in saline).
On day 19 non-fasted mice are to be dosed intra—nasally (lOuL/nostril) with either vehicle
41
WO 2014/195888 PCT/IB2014/061954
or test compound 2 hours before to the start of the final OVA challenge. Two hrs later,
each animal is to be received a final intranasal OVA (3%) challenge). After a further 8 hr,
each animal is to be anaesthetized and nasal lavage is to be carried out by ling 1 ml of
PBS into the posterior nares via a rostrally implanted tracheal cannula extending to a
position that is approximately 1 mm before the posterior nares. This procedure has to be
ed to give a yield of approximately 2 ml of lavage fluid. Total cell numbers in the
nasal lavage fluid samples are to be measured using a haemocytometer. Cytospin smears
of the nasal lavage fluid samples are to be prepared by centrifugation at 1200 rpm for 2
min at RT and d using a Diff-Quik stain system (Dade Behring) for differential cell
counts. Cells are to be counted using oil immersion microscopy.
Assay 17: P01y-l:C-Induced Cell Accumulation in Mice
[168] Specific pathogen-free AIJ mice , 5 weeks old) are to be acclimatized
for seven days prior to the start of the experiment. Animals are then to be randomly
distributed to various groups based on their body weights. Animals are to be administered
with poly (l:C)—LMW 1C; 1 mg/mL, 40 uL) intranasally twice daily for 3 days under
anaesthesia with 3% isoflurane. Animals are to be treated with test compound by intra—
nasally (35 uL of on in 50% DMSO/PBS) 2hr before each poly-l:C treatment.
Twenty four hr after the last poly-l:C challenge, animals are to be anesthetized, the trachea
has to be cannulated and BALF is to be collected. The trations of alveolar
macrophages and phils in BALF are to be determined by using a blood cell counter
and adjusted to l><106 cell/ml. Differential cell count is calculated manually. Forty
microliters of the cell suspension is centrifuged using cytospin 3 to prepare a cell smear.
The cell smear is stained with a blood staining on for differentiation and
microscopically ed to fy eosinophil according to their morphological
characteristics. The number of each cell type among 300 white blood cells in the cell
smear are to be determined and expressed as a percentage, and the number of neutrophils
and macrophages in each BAL fluid are to be calculated.
[169] Although the invention herein has been described with reference to
particular embodiments, it is to be understood that these ments are merely
illustrative of the principles and applications of the present invention. It is therefore to be
understood that numerous modifications may be made to the illustrative embodiments and
that other arrangements may be devised without departing from the spirit and scope of the
present invention as described above. It is intended that the appended claims define the
42
W0 95888 PCT/IB2014/061954
scope of the invention and that methods and ures within the scope of these claims and
their equivalents be covered thereby.
ceutical Composition of Compound Al
Example I
[170] The es described below containing 5 or 10 mg of Compound A1 are
prepared.
Ingredients
Comound A1 4; u:
Microcr stalline cellulose (Avicel PH102) —
H drox r0 0 l cellulose l LF)
Purified Water
Low substituted hydroxyl-oroyl cellulose (L-HPC; LH-l l)
Talc
Colloidal silicon dioxide (Aerosil-200) .09 wt»
Magnesium stearate
Example 11
[171] The capsules described below containing 25, 50, or 100 mg of Compound
A1 are prepared.
—‘&-
[172] All publications and patent and/or patent applications cited in this
application are herein incorporated by reference to the same extent as if each individual
publication or patent application was specifically and individually indicated to be
incorporated herein by reference.
Claims (21)
1. A compound selected from 2-(1-(9H-purinylamino)propyl)(3-fluorophenyl)-4H- chromenone and pharmaceutically acceptable salts thereof.
2. The compound according to claim 1, n the compound is ed from (S)(l- (9H-purinylamino)propyl)(3- fluorophenyl)-4H-chromenone and ceutically acceptable salts thereof.
3. The compound according to claim 2, wherein the nd is free of (l-(9H- purinylamino)propyl)(3-fluorophenyl)-4H-chromenone, and pharmaceutical acceptable salts thereof.
4. The compound of claim 2, wherein the compound has an enantiomeric excess greater than 95%.
5. The compound according to claim 1, wherein the compound is (S)(l-(9H-purin ylamino)propyl)(3-fluorophenyl)-4H-chromenone.
6. The compound of claim 5, wherein the compound is free of (R)(l-(9H-purin ylamino)propyl)(3-fluorophenyl)-4H-chromenone.
7. The nd of claim 5, wherein the compound has an enantiomeric excess greater than 95%.
8. A pharmaceutical composition comprising a compound according to any one of claims 1-7 and at least one pharmaceutically acceptable carrier.
9. Use of a compound according to any one of claims 1-7 in the cture of a medicament for ting a catalytic activity of a PI3 δ kinase present in a cell.
10. Use of a compound according to any one of claims 1-7 in the manufacture of a medicament for inhibiting a catalytic activity of a PI3 γ kinase present in a cell.
11. Use of a compound according to any one of claims 1-7 in the manufacture of a medicament for inhibiting a catalytic ty of a PI3 δ kinase and PI3 γ kinase present in a cell.
12. The use of any one of claims 9-11, wherein the inhibition takes place in a subject suffering from a disease, disorder or condition selected from cancer, a bone disorder, an 44 inflammatory disease, an immune disease, a nervous system e, a metabolic disease, a respiratory disease, thrombosis, and cardiac disease.
13. Use of a compound according to any one of claims 1-7 in the manufacture of a medicament for treating leukemia.
14. Use of a compound according to any one of claims 1-7 in the manufacture of a medicament for treating asthma or chronic obstructive pulmonary disease.
15. Use of a compound according to any one of claims 1-7 in the manufacture of a ment for treating rheumatoid arthritis, psoriasis, lupus or experimental mune encephalomyelitis (EAE).
16. Use of a compound according to any one of claims 1-7 in the manufacture of a medicament for treating chronic lymphocytic ia (CLL), non-Hodgkin lymphoma (NHL), n lymphoma (HL) acute myeloid leukemia (AML), multiple myeloma (MM), small lymphocytic ma (SLL), or indolent non-Hodgkin's ma (I-NHL) disease.
17. Use of a compound of any one of claims 1-7 in the cture of a medicament for the treatment of a disease, disorder or condition that would benefit from inhibiting catalytic activity of a PI3 δ/γ kinase.
18. Use of a compound according to any one of claims 1-7 in the manufacture of a medicament for the treatment of a PI3K associated e, disorder or condition.
19. The use of claim 18, wherein the ment is to be administered with an additional active agent selected from anti-cancer agents, anti-inflammatory agents, immunosuppressive agents, steroids, non-steroidal anti-inflammatory agents, antihistamines, analgesics, and mixtures thereof.
20. The use of claim 18, wherein the PI3K associated e, disorder or condition is an immune system-related disease, a disease or disorder involving inflammation, cancer or other proliferative disease, a hepatic disease or er, or a renal disease or disorder.
21. The use of claim 18, wherein the PI3K associated disease, disorder or condition is selected from leukemia, acute lymphocytic leukemia, acute lymphoblastic leukemia, B-cell lymphoma, T-cell lymphoma, n's ma, non-Hodgkins lymphoma, hairy cell lymphoma, Burkett's lymphoma, acute and chronic myelogenous leukemias, myelodysplastic 45 syndrome and locytic leukemia, psoriasis, rheumatoid arthritis, osteoarthritis, asthma, COPD, allergic rhinitis and lupus erythematosus. 46
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN2501/CHE/2013 | 2013-06-07 | ||
IN2501CH2013 | 2013-06-07 | ||
IN5567CH2013 | 2013-12-03 | ||
IN5567/CHE/2013 | 2013-12-03 | ||
PCT/IB2014/061954 WO2014195888A1 (en) | 2013-06-07 | 2014-06-04 | Dual selective pi3 delta and gamma kinase inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ714465A NZ714465A (en) | 2021-03-26 |
NZ714465B2 true NZ714465B2 (en) | 2021-06-29 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11466006B2 (en) | Dual selective PI3 delta and gamma kinase inhibitors | |
TWI381841B (en) | An immunosuppressive agent and an antitumor agent containing a heterocyclic compound as an active ingredient | |
US20200199133A1 (en) | Selective dual inhibitors of pi3 delta and gamma protein kinases | |
NZ714465B2 (en) | Dual selective pi3 delta and gamma kinase inhibitors | |
OA17589A (en) | Dual selective PI3 delta and gamma kinase inhibitors | |
OA18327A (en) | Substituted chromene derivatives as selective dual inhibitors of Pi3 delta and gamma protein kinases | |
NZ727214B2 (en) | Substituted chromene derivatives as selective dual inhibitors of pi3 delta and gamma protein kinases |